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Abstract 
Severe cases of influenza A virus (IAV) infection are often complicated by concomitant 
bacterial pneumonia or sepsis. Many bacterial species are capable of producing potent 
immunomodulators called superantigens (SAgs), which have the potential to interfere with 
cell-based antiviral immune mechanisms. I asked what effects bacterial SAgs have on both the 
magnitude and the breadth of antiviral CD8+ T cell (TCD8+) responses. Surprisingly, 
administration of SAgs to mice shortly before or after vaccination with IAV increased the 
number of primary TCD8+ responding to select IAV-derived epitopes. T cell receptor staining 
of these SAg-augmented populations revealed expression of Vβ regions that bind SAgs. In vivo 
evaluation of the cytotoxic capability of these cells revealed increased killing of target cells 
pulsed with viral peptides. Memory TCD8+ specific for IAV were also expanded by certain 
SAgs and displayed increased effector functions, though the effect of SAgs on TCD8+ recall 
depended critically on the timing of SAg injection relative to priming and boosting inoculation 
of IAV. Though SAg exposure did not augment local pulmonary TCD8+ responses to active 
IAV infection, it also did not impair these responses as measured by the effect on weight loss 
and viral titre. Finally, I show that SAg-induced augmentation of the magnitude, breadth and 
function of IAV-specific memory TCD8+ can be recapitulated in in vitro experiments utilizing 
human cells. This work elucidates an unexpected role for bacterial SAgs as potential enhancers 
of antiviral immunity in the context of TCD8+-based vaccination strategies. 
 
 
 
 
 
 
 
 
ii 
 
Keywords 
CD8, T cell, superantigen, influenza, co-infection, vaccination, memory, Staphylococcus 
aureus, enterotoxin, immunity, immunodominance 
 
iii 
 
Co-Authorship Statement 
Experiments were performed by the author save for the following: 
Figure 12: Dr. Arash Memarnejadian performed the experiments with rVV and analyzed the 
data. 
Figure 18: Dr. Memarnejadian performed the in vivo killing experiments and analyzed the 
data.  
Figure 29: Dr. Memarnejadian performed two of the in vivo killing experiments and 
analyzed the corresponding data. 
All figures and tables were generated by the author. 
Figures 30, 32 and 33 have been published in the following article: 
Meilleur CE, Wardell CM, Mele TS, Dikeakos JD, Bennink JR, Mu HH, McCormick JK, 
Haeryfar SMM (2018). Bacterial superantigens expand and activate, rather than delete or 
incapacitate, preexisting antigen-specific memory CD8+ T cells. J Infect Dis doi: 
10.1093/infdis/jiy647 [Epub ahead of print] 
  
 
iv 
 
Acknowledgments 
I would like to thank the past and present students and post-doctoral scholars from the 
Haeryfar lab for their help, companionship, and……interesting……office discussions 
throughout my studies. In particular I would like to thank Dr. Peter Szabo for his help getting 
me organized when I first joined the lab and Dr. Arash Memarnejadian for his expert 
assistance and contributions to this thesis. 
Thank you to Delfina Siroen, Janice Kim and Dr. Crystal Engelage for their assistance above 
and beyond as lab technicians/managers. I am especially grateful to Delfina for teaching me 
almost all of the assays I have learned and coming in to the lab at ridiculous times of day or 
night to help me.  
Dr. John McCormick, Dr. Tina Mele and Dr. Jimmy Dikeakos served as my advisory 
committee members, and I am grateful for their expert assistance and valuable feedback 
throughout the course of my studies. I would also like to thank Dr. Hong-Hua Mu, Dr. 
Rodney Dekoter, Dr. Bryan Heit, Dr. Tania Watts and Dr. Suzanne Epstein for contributing 
reagents and/or their input. 
I would also like to thank my friends and family for supporting me throughout my studies 
and listening to angry or excited explanations of experimental results that probably made no 
sense to them. Thanks for listening anways. 
Finally, my deepest thanks to Dr. Mansour Haeryfar for his constant support and mentorship 
throughout my studies. I am lucky to have conducted my studies in his lab, and I will apply 
the lessons I have learned throughout my scientific career.  
 
 
 
 
 
v 
 
Table of Contents 
Abstract……………………………………………………………………………………i 
Keywords………………………………………………………………………………….i 
Co-Authorship Statement………………………………………………………………...iii 
Acknowledgments………………………………………………………………………..iv 
Table of Contents…………………………………………………………………………v 
List of Tables ..................................................................................................................... ix 
List of Figures ..................................................................................................................... x 
List of Abbreviations ....................................................................................................... xiii 
Chapter 1: Introduction ....................................................................................................... 1 
1.1 Host responses to infection……………………………………………………………1 
1.1.1 Innate immunity……………………………………………………………….....1 
1.1.2 Adaptive immunity………………………………………………………………2 
1.1.2.1 Humoral response…………………………………………………………3 
1.1.2.2 Cell-mediated response……………………………………………………4 
1.1.2.3 Antigen processing and presentation………………………………………6 
1.1.2.3.1 Cross-presentation and Cross-Priming…………………………...7 
1.2 Immunopathology caused by bacterial infections……………………………………...8 
1.2.1 Infection by Gram-positive bacteria………………………………………………8 
1.2.1.1 Staphylococcus aureus infections………………………………………….8 
1.2.2 Bacterial superantigens…………………………………………………………...9 
1.3. Immunopathology caused by viral infections……………………………………….11 
1.3.1 General overview of virally-induced immunopathology……………………….11 
1.3.2 Influenza A virus……………………………………………………………….12 
1.3.2.1 Structure and replication cycle…………………………………………..13 
 
vi 
 
1.3.2.2 Pathogenesis……………………………………………………………...14 
1.3.2.3 Antigenic shift and drift………………………………………………….15 
1.4. Immune responses to influenza A virus……………………………………………..16 
1.4.1 Innate immune responses to IAV………………………………………………16 
1.4.2 Adaptive immune responses to IAV………………...........................................18 
1.4.2.1 Humoral responses………………………………………………………18 
1.4.2.2 Cell-mediated responses…………………………………………………19 
1.4.3 Immune evasion mechanisms…………………………………………………..20 
1.4.4 Vaccination against influenza A virus……………………………………….…21 
1.5 Animal models of influenza A virus infection and vaccination…………………….22 
1.5.1 Mice……………………………………………………………………………22 
1.5.2 Ferrets………………………………………………………………………….23 
1.5.3 Guinea pigs………………………………………………………………….....24 
1.5.4 Nonhuman primates……………………………………………………………24 
1.6 CD8+ T cell responses to influenza A virus…………………………………………25 
1.6.1 Naïve IAV-specific CD8+ T cells………………………………………………25 
1.6.2 Phases of the CD8+ T cell response to IAV……………………………………26 
1.6.2.1 Priming of naïve TCD8+…………………………………………………26 
1.6.2.2 TCD8+ effector function…………………………………………………27 
1.6.2.3 Recall and memory responses to IAV…………………………………...28 
1.6.3 Immunodominance in CD8+ T cell responses to IAV………………………….29 
1.7. Coinfection with IAV and Gram-positive bacteria………………………………….30 
1.7.1 IAV infection of septic and toxic shock patients……………………………….30 
1.7.2 Secondary bacterial pneumonia complicating IAV infection…………………..31 
1.7.3 Superantigens and IAV…………………………………………………………32 
1.8. Rationale and hypothesis…………………………………………………………….37 
 
vii 
 
1.9. Specific aims…………………………………………………………………………37 
1.10. References………………………………………………………………………….38 
Chapter 2: Materials and Methods .................................................................................... 59 
2.1 Ethics........................................................................................................................... 59 
2.2 Mice…………………………………………………………………………………..59 
2.3 Cell culture…………………………………………………………………………...59 
2.4 Preparation and injection of SAg…………………………………………………….60 
2.5 Preparation and administration of IAV………………………………………………60 
2.6 Preparation and administration of rVV………………………………………………61 
2.7 Intracellular cytokine staining………………………………………………………..62 
2.8 Surface staining………………………………………………………………………63 
2.9 Tetramer staining of mouse TCD8+………………………………………………….64 
2.10 CD107a detection…………………………………………………………………..64 
2.11 In vivo killing assay…………………………………………………………………64 
2.12 RT-PCR of lung and BAL samples for detection of IAV…………………………..65 
2.13 Detection of infectious IAV by TCID50 assay………………………………………65 
2.14 IAV-specific antibody titration……………………………………………………...66 
2.15 Human PBMC preparation and culture……………………………………………...67 
2.16 Dextramer and tetramer staining of human PBMCs………………………………...68 
2.17 51Cr release assay……………………………………………………………………69 
2.18 Flow cytometry and analysis………………………………………………………..69 
 
viii 
 
2.19 Statistical analyses…………………………………………………………………..69 
2.20 References…………………………………………………………………………..70 
Chapter 3: Results ............................................................................................................. 72 
 
3.1 In vitro stimulation of BALB/c splenocytes with SEB decreases the detectability of  
TCD8+ bearing certain Vβ regions……………………………………………………….72 
3.2 SEB alters the IAV-specific immunodominance hierarchy in a mouse model of IAV   
vaccination……………………………………………………………………………….74 
3.3 Augmentation of the response to IAV by SEB lasts several days after the peak TCD8+ 
response to IAV………………………………………………………………………….86 
3.4 TCD8+ expanded by SEB are functional in terms of degranulation and cytotoxic 
ability…………………………………………………………………………………….88 
3.5 SEB increases the magnitude of the IAV-specific TCD8+ response regardless of the IAV 
strain used for vaccination……………………………………………………………….92 
3.6 SEB administration before infection with recombinant vaccinia virus reduces the number 
of VV-specific TCD8+…………………………………………………………………...94  
3.7 Changes in the ID hierarchy are driven by Vβ expression among different TCD8+ 
populations……………………………………………………………………………….96 
3.8 Changing the order of IAV and SEB administration results in increased TCD8+ responses 
towards all epitopes……………………………………………………………………..102 
 
3.9 The effect of SEB in a prime-boost model of IAV vaccination depends on SEB 
administration time……………………………………………………………………...108 
 
3.10 Local TCD8+ responses to intranasal IAV infection are not negatively affected by  
SEB……………………………………………………………………………………..116 
3.11 SEB greatly augments the immunodominant NP147 response in the context of IAV-specific 
memory………………………………………………………………………...126 
3.12 Human IAV-specific memory responses are augmented by SEB………………...130 
3.13 References…………………………………………………………………………138 
Chapter 4: Discussion ..................................................................................................... 143 
4.1 References…………………………………………………………………………..153 
Curriculum Vitae ............................................................................................................ 159 
 
ix 
 
List of Tables 
Table 1: Human blood donor demographic information and donor identification……..67 
  
 
 
x 
 
List of Figures 
Figure 1. Schematic representation of the “hole in the repertoire” posited to exist after SAg 
exposure……………………………………………………………………………………...36 
Figure 2. In vitro culture of BALB/c splenocytes with SEB results in reduced detectability of 
TCD8+ bearing SEB-binding Vβ regions……………………………………………………73 
Figure 3. Effect of SEB on the primary TCD8+ response to IAV in BALB/c mice………..76 
Figure 4. Geometric mean fluorescence intensity (gMFI) of IFNγ-FITC for three selected 
splenic epitope-specific populations………………………………………………………...79 
Figure 5. Percentage (A) and absolute number (B) of TCD8+ in the spleen producing IFNγ in 
response to stimulation with IAV-infected J774 cells………………………………………81 
Figure 6. Effect of SEB on the primary TCD8+ response to IAV in BALB/c mice………..83 
Figure 7. Effect of SEB on the (A) percentage and (B) number of CD3+ CD8+ epitope-
specific splenocytes as determined by tetramer staining…………………………………....85 
Figure 8. Primary response to IAV over the course of 11 days in PBS- versus SEB-injected 
animals………………………………………………………………………………………87 
Figure 9. SEB increases the percentage and absolute number of IAV-specific TCD8+ 
expressing CD107a………………………………………………………………………….89 
Figure 10. Lytic ability of splenic epitope-specific TCD8+ after 4 hours of incubation  
in vivo……………………………………………………………………………………….91 
Figure 11. Primary splenic TCD8+ response to different strains of IAV after SEB treatment, 
as determined by ICS for IFNγ expression…………………………………………………93 
Figure 12. The TCD8+ response to vaccinia virus is reduced by administration of SEB…95 
Figure 13. Expression of different Vβ regions among splenic TCD8+ specific for three 
different epitopes…………………………………………………………………………..97 
 
xi 
 
Figure 14. Administration of MAM augments the primary TCD8+ response to IAV in a 
similar manner as SEB…………………………………………………………………….99 
Figure 15. SEA administration does not change the IAV-specific TCD8+ ID hierarchy..101 
Figure 16. Effect of SEB administration on the primary splenic TCD8+ response to IAV, 
where SEB is administered 3 days before the peak IAV-specific response……………...103 
Figure 17. Effect of SEB administration on the primary splenic TCD8+ response to IAV, 
where SEB is administered during the peak IAV-specific response……………………..105 
Figure 18. The kinetics of NP147-specific CD8
+ T cell-mediated cytotoxicity in PBS- and 
SEB-treated mice…………………………………………………………………………107 
Figure 19. SEB administration 3 days before IAV vaccination greatly increases the 
percentage and absolute number of KLRG1- CD127+ memory precursor cells that are specific 
for NP147 and HA518, as determined by tetramer staining…………………………………109 
Figure 20. SEB administration before a priming dose of PR8 selectively increases the 
TCD8+ response to IAV as measured 7 days after a booster vaccination with SEQ.12…..111 
Figure 21. SEB administration before a boosting dose of SEQ.12 decreases the TCD8+ 
response to IAV as measured 7 days later…………………………………………………113 
Figure 22. Splenic TCD8+ specific for NP147 and HA518 display increased expression of 
anergy markers and lower Ki67 expression when SEB is given before the boosting dose of 
IAV………………………………………………………………………………………...115 
Figure 23. Weight loss of BALB/c mice infected intranasally with a sublethal dose of IAV 
(PR8) or PBS three days after intraperitoneal injection of SEB or PBS………………......117 
Figure 24. Response to IAV infection in the spleen, lungs and BAL of BALB/c mice treated 
with PBS or SEB prior to virus exposure………………………………………………….119 
Figure 25. IAV titre in the lungs and BAL fluid of mice infected 4 days prior with IAV 
(PR8)………………………………………………………………………………………121 
 
xii 
 
Figure 26. Relative number of IAV viral particles in the lung and BAL of mice infected with 
sublethal IAV (PR8) after i.p. injection of SEB…………………………………………..123 
Figure 27. Antibody titres in the serum of mice treated with SEB or PBS before IAV 
infection (0.3 MLD50)……………………………………………………………………..125 
Figure 28. The NP147- specific memory CD8
+ T cell population is expanded by contact with 
SEB………………………………………………………………………………………..127 
Figure 29. IAV memory mice injected with SEB three days prior to in vivo killing assay 
have significantly more killing of NP147-pulsed target cells……………………………….129 
Figure 30. Human M158-specific memory TCD8
+ are expanded by SEB………………...131 
Figure 31. M158-specific memory CD8+ T cells from healthy human donors expand in the 
presence of MAM SAg…………………………………………………………………….133 
Figure 32. SEB induces expansion of M158-specific TCD8
+ but not memory TCD8+ specific 
for CMV-derived pp65495………………………………………………………………….135 
Figure 33. M158-specific TCD8
+ from three healthy donors that have been incubated with 
SEB display the ability to kill target cells pulsed with M158 peptide………………………137 
 
 
 
 
 
 
 
 
xiii 
 
List of Abbreviations 
ACK - ammonium chloride potassium 
ADCC - antibody-dependent cell-mediated cytotoxicity 
Ag - antigen 
AICD - activation-induced cell death 
ANOVA - analysis of variance 
APC - antigen-presenting cell 
BAL - bronchoalveolar lavage 
BCR - B cell receptor 
BFA - brefeldin A 
BSA - bovine serum albumin 
CCL - chemokine (C-C motif) ligand 
CFSE - Carboxyfluorescein succinimidyl ester 
CLIP - Class II-associated invariant chain peptide 
CLP - cecal ligation and puncture 
CTL - cytotoxic T lymphocyte 
DC - dendritic cell 
DEPC - Diethylpyrocarbonate 
DMEM - Dulbecco's modified Eagle medium 
DMSO - dimethylsulphoxide 
DNA - deoxyribonucleic acid 
dsRNA - double-stranded ribonucleic acid 
ELISA - enzyme-linked immunosorbent assay 
ER - endoplasmic reticulum 
FACS - fluorescence activated cell sorting 
FCS - fetal calf serum 
FPLC - fast protein liquid chromatography 
GM-CSF - granulocye-macrophage colony stimulating factor 
gMFI – geometic mean fluorescence intensity 
HA - hemagglutinin 
HCV - hepatitis C virus 
HK - A/Hong Kong/01/1968 H3N2 
HNP - human neutrophil peptide 
HPLC - high-performance liquid chromatography 
i.n. - intranasal 
i.p. - intraperitoneal 
IAV - influenza A virus 
ICAM - intercellular adhesion molecule  
ICS - intracellular cytokine stain 
IFN - interferon 
IL - interleukin 
 
xiv 
 
KLH - keyhole limpet hemocyanin 
KLRG1 - Killer Cell Lectin Like Receptor G1 
LAG3 – lymphocyte-activation gene 3 
LPS - lipopolysaccharide 
M1 - matrix protein (influenza A virus) 
MAM - Mycoplasma arthritidis mitogen 
MARCO - macrophage receptor with collagenous structure 
MDCK - Madin-Darby canine kidney 
MHC - major histocompatibility complex 
MLD50 - 50% mouse lethal dose 
NA - neuraminidase 
NF-κB - nuclear factor kappa-light-chain-enhancer of activated B 
cells 
NHP - nonhuman primate 
NK - natural killer 
NLR - NOD-like receptor 
NOD - nucleotide oligomerization domain 
NP - nucleoprotein 
NS1 - non-structural protein 1 
NT60 - A/Northern Territory/60/1968 H3N2 
OAS - original antgienic sin 
OVA - ovalbumin 
PA - polymerase acidic 
PAMP - pathogen-associated molecular pattern 
PB - polymerase basic 
PBMC - peripheral blood mononuclear cell 
PBS - phosphate buffered saline 
PD-1 – Programmed death 1 
PEC - peritoneal exudate cell 
pfu - plaque-forming unit 
PKR - protein kinase R 
PR8 - A/Puerto Rico/8/1934 H1N1 
PRR - pattern recognition receptor 
RIG - retinoic acid inducible gene 
RNA - ribonucleic acid 
RPMI - Roswell Park Memorial Institute 
RT-PCR - Reverse transcription polymerase chain reaction 
rVV - recombinant vaccinia virus 
SAg - superantigen 
SEA - Staphylococcal enterotoxin A 
SEB - staphylococcal enterotoxin B 
SEQ.12 - sequential 12 
 
xv 
 
SMH - somatic hypermutation 
SP-D - surfactant protein D 
ssRNA - single-stranded ribonucleic acid 
TAP - Transporter associated with antigen processing 
TCD4+ - CD4+ T cell 
TCD8+ - CD8+ T cell 
TCID50 - 50% tissue culture infectious dose 
TCR - T cell receptor 
TdT - terminal deoxynucleotidyl transferase 
TLR - Toll-like receptor 
TNF - tumour necrosis factor 
TPCK -  L-1-Tosylamide-2-phenylethyl chloromethyl ketone 
TRAIL - TNF-related apoptosis-inducing ligand 
Treg - T regulatory cell 
TSS - toxic shock syndrome 
TSST-1 - toxic shock syndrome toxin-1 
vRNP - viral ribonucleoprotein 
 
 
 
 
 
 
 
 
 
 
1 
 
 
Chapter 1: Introduction 
1.1 Host responses to infection 
The mammalian immune system has evolved to provide effective protection against a wide 
array of bacteria, parasites and viruses. The components of the immune system are divided 
into two main arms, though there are some types of immune cells with characteristics of 
both. The innate arm of the immune system is fast-acting but non-specific, or polyspecific 
at best, offering protection against pathogens by recognizing evolutionarily-conserved 
molecular motifs associated with infection or danger signals (1). Adaptive immunity takes 
longer to develop, but is highly specific and capable of eliminating pathogens and provides 
long-term memory against future infections (2). Both arms of the immune system are often 
necessary for protection against pathogens. 
1.1.1 Innate immunity 
The cells of the innate immune system are the first line of defence against infection by 
pathogenic organisms. Overall, the role of innate immunity is to keep infections in check 
and prime the adaptive immune system for a more targeted response. Another defining 
feature of the innate response is that it does not typically exhibit memory; that is, the 
magnitude of the response to a given immunological insult is usually equivalent regardless 
of prior exposures.  
The components of the innate immune system recognize molecules that are associated with 
pathogens or other immunological insults. These pattern recognition receptors (PRRs) 
recognize conserved microbial molecules (pathogen associated molecular patterns, or 
PAMPs) and other danger signals that are present in the body soon after infection and are 
the same in every individual of a given species (3). Perhaps the most well-known of these 
components are Toll-like receptors (TLRs) that are found as dimeric proteins expressed by 
some innate immune cells. TLRs recognize certain types of molecules derived from 
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pathogens; for example, TLR4, in collaboration with CD14, recognizes the presence of 
bacterial lipopolysaccharide (LPS) and activates intracellular signalling cascades leading 
to the activation of the innate immune system (4). In the same vein, nucleotide 
oligomerization domain (NOD)-like receptors (NLRs) survey the intracellular environment 
for microbial products and other danger-associated signals (5). Many other types of PRRs 
exist, but all function to recognize danger to the host and to mobilize the immune system 
to deal with the threat. 
The innate immune system also includes cells that are capable of quickly responding to 
and eliminating pathogens. The first innate immune cells to respond to infection are often 
neutrophils, which are short-lived but abundant phagocytic cells. They respond to an 
infection by phagocytosing pathogens and producing toxic mediators to control infection 
(6). Macrophages are able to efficiently phagocytose targets and produce chemokines that 
attract other immune cells to the site of infection (7). Innate immune cells are also capable 
of recognizing and responding to the absence of markers that should be expressed on a 
normal cell. Natural Killer (NK) cells look for missing ‘self’ signals on the surface of host 
cells, which can be indicative of abnormal function (such as cancer) or viral infection. NK 
cells can then lyse the abnormal target cell through the secretion of perforin and granzymes 
(8). In addition to the functions mentioned above, the innate immune system is also 
responsible for activating the adaptive arm of immunity. Dendritic cells (DCs) link the two 
arms by taking up extracellular material and presenting processed antigens to certain cells 
of the adaptive immune system. By presenting antigen to the appropriate cell type and by 
expressing costimulatory molecules they serve as the bridge between the innate and 
adaptive arms of the immune system (9). 
1.1.2 Adaptive immunity 
The distinguishing features of the adaptive arm of the immune system include a fine 
specificity and capacity for memory. Unlike innate immunity, the adaptive system requires 
several days after initial antigen contact before mounting an effective response. Adaptive 
immune cells are able to recognize specific pathogen-derived peptides and eliminate their 
targets while causing less collateral damage than the more general targeting of the innate 
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immune arm. Adaptive immune responses also generate immunological memory, resulting 
in the generation of long-lived cells that are capable of rapid activation upon encountering 
the same antigen. These secondary responses quickly eliminate pathogens before they have 
the chance to cause damage to the host. Adaptive immunity is typically separated into two 
branches, each necessary for effective immunity.  
1.1.2.1 Humoral response 
The main cellular components of the humoral immune system are B cells, which largely 
exert their effector function through the production of antibodies specific for given 
antigens. B cells arise from common hematopoetic stem cell precursors in the bone 
marrow. The genes that encode segments of the B cell receptor (BCR) are rearranged 
independently on a per-cell basis, such that each B cell has a BCR specific for a unique 
epitope. Immature B cells first express surface immunoglobulin of the IgM isotype before 
adding surface IgD expression after exiting the bone marrow. These mature but antigen-
inexperienced B cells circulate through the lymph nodes and the lymphatic system until 
they encounter their cognate antigen (10). 
Upon cognate antigen encounter, B cells upregulate adhesion molecules such as 
lymphocyte function-associated antigen 1 (LFA-1), which causes them to migrate to 
secondary lymphoid tissues such as the spleen and lymph nodes (11). However, the vast 
majority of B cells typically find their cognate antigen when circulating through the 
secondary lymphoid tissue itself. After antigen encounter in the spleen or lymph nodes, B 
cells will traffic to the red pulp or primary lymphoid follicle, respectively. They will then 
proliferate to form a primary focus in the spleen or a germinal center in the lymph node. 
The entire process, from antigen encounter to proliferation, takes about five days to 
complete (12). 
Within the germinal center the proliferating B cells undergo class-switching and somatic 
hypermutation (SMH). Class switching involves the splicing of the epitope-specific V-
region of the B cell receptor DNA and ligation to a new C-region, which changes the 
isotype of the antibody that the cell produces. B cells start out by producing exclusively 
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IgM molecules, but after class-switching they may gain the ability to produce IgA, IgE or 
IgG. SMH can occur at the same time as class-switching and involves the creation of single 
point mutations in the V-region of the immunoglobulin heavy and light chains. This 
process, known as affinity maturation, produces many B cell clones with a lower affinity 
for the target epitope and a few clones that have a higher affinity. The clones with lower 
affinity die by apoptosis due to lack of antigen binding, while the higher affinity clones are 
positively selected for and continue to proliferate. This whole process results in B cells that 
produce antibodies with a higher affinity for the target antigen than the original clone. The 
surviving, high-affinity B cells then continue to proliferate and differentiate into plasma 
cells, which secrete large amounts of antibody to deal with the infection, or long-lived 
memory B cells that continue to reside in the lymph node (13).   
If the host then re-encounters the pathogen that the memory B cell response was developed 
against, the memory B cells are quickly re-activated and differentiate into plasma cells, 
which produce large amounts of high-affinity antibody. This rapid antibody production 
after secondary exposure requires a much lower dose of antigen than the primary response 
(14), eliminating the pathogen much more quickly. The production and maintenance of an 
antigen-specific pool of memory B cells is the end goal of many different vaccination 
protocols (15).  
1.1.2.2 Cell-mediated response 
T cells are the main players in the cell-mediated arm of the adaptive immune system. Like 
B cells, they arise from common lymphoid progenitors in the bone marrow. Unlike B cells, 
T cells must traffic to the thymus and receive the appropriate signals from the thymic 
stroma before they can mature (16). T cell progenitors in the thymus first undergo 
rearrangement of their germline V, D and J regions to generate a unique T cell receptor 
(TCR) (17). This process, known as V(D)J recombination, involves the cutting and pasting 
together of different gene segments. Though there are only a set number of V, D and J 
segments available for recombination, TCR diversity is greatly increased by the action of 
terminal deoxynucleotidyl transferase (TdT), which adds strings of random nucleotides to 
the junctions of the different gene segments. In this way, the potential number of unique 
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TCRs in a given individual can exceed 1015 (18). T cell clones that successfully complete 
V(D)J recombination enter the double positive stage, characterized by the simultaneous 
surface expression of CD4 and CD8. The cells then undergo positive and negative 
selection, which eliminates clones that are unable to bind self-major histocompatibility 
complex (MHC) with sufficient affinity or recognize self-derived peptides. Though 98% 
of T cell precursors are eliminated by this point, those that have survived become either 
single-positive CD4+ (TCD4+) or CD8+ T cells (TCD8+) before travelling to secondary 
lymphoid organs to await encounter with their cognate antigen (19). 
T cells are activated upon TCR-mediated recognition of cognate peptides presented in the 
context of MHC I (for TCD8+) or MHC II (for TCD4+). Optimal activation requires the 
presence of the appropriate costimulatory molecules on antigen-presenting cells (APCs), 
as well as the presence of appropriate cytokines (20, 21). The combination of these three 
signals results in the induction of intracellular signalling pathways within the T cell, 
stimulating proliferation and initiation of effector functions. Though several different types 
of T cells (differentiated by the composition of their TCR and ultimate effector function) 
exist, the most common and most extensively studied are CD4+ and CD8+ αβ T cells. 
The main function of TCD4+ is to provide help to B cells and macrophages. CD4+ T cells 
provide help to their cognate B cells, allowing them to survive, proliferate, and secrete 
antibody. In addition, TCD4+ can be influenced by the cytokine milieu to acquire a Th1 or 
Th2 phenotype (22). Th1 responses are classically marked by the production of 
inflammatory cytokines such as interferon (IFN)γ, which are helpful during immune 
responses against intracellular pathogens and cancerous cells. Th2 responses are 
characterized by the production of interleukin (IL)-4, IL-5 and IL-13, which are helpful 
during antibody responses against extracellular pathogens such as most bacteria and 
parasites (23, 24, 25). Activated TCD8+ are responsible for finding and killing target cells 
that express their cognate antigen. Typically, TCD8+ antigens are derived from intracellular 
peptides that can originate from the host or from pathogens inside the cell (26). Almost all 
cell types express MHC I, which serves as a monitoring system to ensure that the cell is 
not infected by viruses or producing any abnormal peptides. If an activated TCD8+ 
recognizes its cognate peptide presented in the context of MHC I on the surface of a cell, 
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the TCD8+ will bind MHC I through its TCR and induce target cell death through one of 
several pathways. These include Fas/FasL interaction, activation of the TNF-related 
apoptosis-inducing ligand (TRAIL) pathway, tumour necrosis factor (TNF)α production, 
and induction of the perforin/granzyme pathway (27, 28, 29). After resolution of the 
immunological insult, a subpopulation of the epitope-specific TCD8+ remain as long-lived 
memory cells that rapidly proliferate and differentiate into cytotoxic effector cells upon re-
encounter with antigen. 
1.1.2.3 Antigen processing and presentation 
Integral to the initiation of an adaptive immune response is the processing and presentation 
of protein antigens (Ags) from pathogens or abnormal host cells. Antigen processing and 
presentation can be divided into two general categories depending on whether the Ag 
originates from inside the antigen-presenting cell (APC) or from outside the cell. In 
general, antigens from extracellular sources or from cellular vesicles are presented on MHC 
II molecules for presentation to CD4+ T cells, while antigens arising from the cytosol of a 
cell are processed through a different pathway for loading onto MHC I and eventual 
presentation to CD8+ T cells (30). 
The generation of peptides for presentation on MHC II relies on the endocytosis of 
extracellular pathogens by APCs such as macrophages, activated B cells and dendritic 
cells. MHC II molecules are located in the endoplasmic reticulum (ER), where they are 
loaded with a class II-associated invariant-chain peptide (CLIP) to prevent promiscuous 
binding to other host peptides that may be present in the ER. The MHC II molecule resides 
in an acidified endosome, which can fuse with other vesicles containing material that has 
been obtained from outside the cell. These vesicles contain peptides derived from the 
breakdown of extracellular proteins, which is mediated by low pH and the action of 
proteases. In order to successfully bind MHC II the peptides need to be 15-24 residues 
long, as shorter or longer peptides do not form a stable complex (31). However, before 
these pathogen-derived peptides can bind the MHC II molecules, they must release CLIP. 
This is achieved by the class II-like molecule HLA-DM, which binds to the MHC II:CLIP 
complex, thus dissociating CLIP from MHC II. The endosomal pathogen-derived peptides 
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are subsequently able to bind the MHC II’s peptide binding groove, which allows 
translocation of the MHC II:peptide complex to travel to the cell surface. MHC II is 
typically only expressed by APCs, as the presentation of MHC II antigens activates CD4+ 
T cells, which can help B cells to secrete antibody and activate macrophages to eliminate 
extracellular threats. 
The MHC I pathway is geared towards the processing and presentation of antigens obtained 
from the cytosol. Proteins present in the cytosol are degraded by the immunoproteasome 
(32), which preferentially produces peptides that are of the right length (8-11 residues) to 
fit in the peptide-binding pocket of MHC I (33). These peptides are then delivered from 
the cytosol to the ER by transporters associated with antigen processing (TAP) 1 and 2 
molecules, where they can be loaded onto MHC I molecules. MHC I is retained in the ER 
in a partially folded state stabilized by calnexin until binding of β2-microglobulin. The 
MHC I complex is then released from calnexin to bind calreticulin and tapasin, which 
brings the complex into close proximity with TAP. Upon peptide loading, the MHC I 
complex is stabilized and transported to the cell surface. All nucleated cells express MHC 
I and present cytosol-derived peptides as a form of immune surveillance for cancerous cells 
and intracellular infection. Thus, cells that display pathogen-derived peptides on MHC I 
are killed by cognate CD8+ T cells. Furthermore, any cell that does not express MHC I and 
displays activating receptors for NK cells will be lysed by NK cells (34), though there are 
exceptions to this rule. For example, erythrocytes express inhibitory receptors along with 
CD47 as an alternative marker of “self” (35).  
1.1.2.3.1 Cross-Presentation and Cross-Priming 
In some cases, MHC I molecules can present peptides to TCD8+ cells derived from 
extracellular sources. This is known as cross-presentation and is important for the TCD8+ 
response to certain viruses and cancers (36). DCs have the ability to phagocytose 
extracellular material such as dead or dying cells that may contain proteins derived from 
viruses. The extracellular material is then transported from the phagosome to the cytosol 
where it can be degraded by the immunoproteasome, transported via TAP into the ER and 
subsequently loaded into MHC I molecules for presentation to naive CD8+ T cells. In this 
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case, the presenting DC is not immediately killed by the TCD8+ cell. Rather, the formerly 
naive TCD8+ becomes an effector cell and is induced to search out and destroy host cells 
that present its cognate peptide in the context of MHC I. This is important for the activation 
of naive TCD8+ by dendritic cells, as not all viruses can infect APCs (37, 38). In addition, 
cross-priming is important in cancers where the tumour cells fail to express MHC I yet 
escape killing by NK cells (39, 40). 
1.2. Immunopathology caused by bacterial infections 
Though the immune system has evolved to be indispensable for human health, some 
pathogens are capable of skewing the components of the immune system towards a harmful 
response. This can be achieved through multiple mechanisms, from formation of harmful 
antigen and antibody complexes to direct activation of immune cells by bacterial toxins or 
by inflammatory bacterial products. 
1.2.1 Infection by Gram-positive bacteria 
Gram-positive bacteria are so-called because of their thick cell wall layers of 
peptidoglycan, which retain the crystal violet component of the Gram stain mixture in 
contrast to Gram-negative organisms, which are only stained by the safranin component. 
Current common Gram-positive infections include those caused by Streptococcus and 
Enterococcus species, with an increasingly prominent role being played by multiple-drug 
resistant species of Staphylococcus (41). 
1.2.1.1 Staphylococcus aureus infections 
Staphylococcus aureus is a common bacterium that asymptomatically colonizes roughly 
30% of the human population (42). S. aureus can cause disease in a myriad ways depending 
on the expression of different virulence factors by the bacterium and the route of entry into 
the body. Most infections with S. aureus occur in the skin and soft tissue, with more than 
one million cases in the United States requiring medical intervention (43). More serious, 
life-threatening diseases caused by S. aureus include toxic shock syndrome, sepsis and 
endocarditis. In the context of these diseases, S. aureus has the ability to induce extensive 
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immunopathology. It is known to be able to survive inside neutrophils, which protects the 
bacteria from killing by other immune cells (44). S. aureus has also been shown to exploit 
this ability to survive inside highly mobile immune cells such as macrophages, using them 
as vehicles for dissemination into other tissues (45). Secreted toxins such as α-hemolysin 
and Panton-Valentine leukocidin promote lysis of innate immune cells such as monocytes 
and neutrophils, disrupting the immune response while catalyzing the release of additional 
inflammatory signals (in the form of dead cells and debris) that can result in tissue damage 
(46). 
1.2.2 Bacterial superantigens 
A major mediator of bacterial infection-induced immunopathology is the action of a class 
of proteins known as superantigens (SAgs). The most well-studied SAgs are those 
produced by S. aureus and S. pyogenes; SAgs from both species of bacteria function in a 
similar way. Mycoplasma arthritidis can also produce a SAg called Mycoplasma arthritidis 
mitogen (MAM), though this has received less attention as M. arthritidis is not a human 
pathogen (47). SAgs tend to be small secreted proteins that are remarkably stable, with 
some resistant to  denaturation after desiccation and boiling for short periods of time (48). 
Their defining feature is the ability to activate large numbers of T cells to proliferate and 
secrete inflammatory cytokines (49). In vivo, this results in a cytokine storm, which has 
been implicated in the pathogenesis of diseases such as bacterial sepsis and toxic shock 
syndrome (50). Bacterial SAgs also have potential as agents of bioterrorism, notably 
through induction of a fatal respiratory reaction after inhalation (51).  
SAgs from S. aureus and S. pyogenes function through similar mechanisms. They both 
bind the lateral surface of the human MHC II molecule and the Vβ region of CD4+ and 
CD8+ TCRs, cross-linking the two molecules together regardless of the peptide occupying 
the peptide-binding groove (52, 53). This causes activation of the T cell, resulting in 
vigorous proliferation and secretion of inflammatory cytokines. In this manner up to 30% 
of all T cells in a given individual may be provoked to proliferate (50). The fate of these T 
cells after activation is controversial and may depend on the activation state of the cell 
before contact with the SAg. Most previous research suggests that T cells activated by 
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SAgs are eliminated through activation-induced cell death, or become anergized through 
the lack of appropriate costimulation by APCs (54, 55). However, other studies using 
different methods to assess the fate of antigen-specific T cells and different timepoints after 
SAg administration indicate that this may not be the case (56). TCR internalization is one 
outcome of T cell activation and this has complicated investigations into the effects of 
SAgs (57). In addition, SAgs have different Vβ binding profiles; that is, different SAgs can 
bind to only a few different Vβ regions out of the 60 or so that are expressed in humans. 
For example, staphylococcal enterotoxin B (SEB) is known to bind to Vβ 1, 3, 6.4, 7, 12.2, 
13.2, 14, 15.1, 17.1 and 20, while toxic shock syndrome toxin-1 (TSST-1) predominantly 
binds Vβ 2.1 (58). 
SAgs derived from S. aureus are of particular interest because of their multifarious roles in 
human disease. S. aureus encodes a number of superantigenic enterotoxins, so named 
because of their implication in instances of foodborne illness. Ingestion of less than 1 μg 
of SEB in contaminated food is sufficient to induce cramping, diarrhea and vomiting within 
four hours of eating contaminated food (59). Staphylococcal SAgs are also the main 
inducers of the cytokine storm accompanying TSS and sepsis, which is predominantly a 
result of the massive release of TNFα, IL-2 and IFNγ, with a crucial role also being played 
by IL-17 (60, 61). S. aureus is also the pathogen responsible for perhaps the most well-
known instance of SAg-mediated disease. In the 1970s, there was an outbreak of menstrual 
toxic shock syndrome (TSS), which was later traced to the use of high-absorbency tampons 
that encouraged the growth of S. aureus (62, 63). The incidence of menstrual TSS 
plummeted after these tampons were phased out, but non-menstrual TSS was and continues 
to be a public health problem (64). In cases of non-menstrual TSS caused by S. aureus the 
SAgs that are responsible for pathogenesis are staphylococcal enterotoxins A, B and C 
(SEA, SEB and SEC) (65). There is currently no good treatment for SAg-mediated 
systemic diseases such as TSS or sepsis besides supportive care. 
1.3. Immunopathology caused by viral infections 
Many viral species are also capable of inducing immunopathological responses as a side 
effect of infection. In some cases the virus can take advantage of the immunopathological 
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reaction to increase the production of viral particles, while in other cases it is deleterious 
to both the virus and the host. The following section will briefly cover some examples of 
virus-induced immunopathology, with a special focus on influenza A virus (IAV). 
1.3.1 General overview of virally-induced immunopathology 
Viral infection can be characterized as either acute or chronic; that is, replicating for a short 
period of time in the host before clearance by the immune system (or death of the host), or 
persisting for an indeterminate length of time due to evasion or disruption of host immune 
responses. Both viruses that cause acute infections and viruses that cause chronic infections 
can induce immunopathology. Hepatitis C virus (HCV) is an example of a virus that causes 
a chronic infection accompanied by CD8+ T cell-mediated destruction of bystander 
hepatocytes, which can result in cirrhosis of the liver (66). Hepatitis B virus is another 
chronic pathogen that instigates an immunopathological response. Antibodies generated 
against this virus can form complexes with viral particles, which then become trapped in 
dense capillary beds such as those found in the kidney (67). This induces aberrant 
activation of the complement cascade, resulting in tissue damage and potential loss of 
organ function. Acute viral infections can also be potent inducers of immunopathological 
reactions. One interesting case is that of Dengue virus, which can induce immunopathology 
through molecular mimicry. In mouse models it was found that the viral NS1 protein 
induces the generation of IgM antibodies that cross-react with host platelets (68). This 
results in thrombocytopenia and the subsequent hemorrhage that characterizes severe cases 
of Dengue infection. Another acute virus that can induce a great degree of 
immunopathology is IAV, especially the novel pandemic strains that can arise from the 
exchange of genetic material between human and animal IAVs. In the most severe cases 
IAV can be responsible for the induction of a so-called cytokine storm, which can be 
described as a self-perpetuating positive feedback loop largely initiated by the cells of the 
immune system in response to infection (69). Infection of airway epithelial cells leads to 
the production of type I IFN, which signals to alveolar macrophages and other innate 
immune cells, causing them to migrate to the site of infection and release more 
inflammatory mediators. The release of these cytokines (notably TNFα) and chemokines 
in turn brings in more responding immune cells, which continues to amplify the 
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inflammatory signal until it is beyond the ability of  anti-inflammatory signals to attenuate. 
This sort of positive feedback loop has been shown to occur more often in cases of severe 
infection of young, immunocompetent people infected with antigenically novel IAVs (70). 
The high propensity of IAV to rapidly change its proteins (i.e. an antigenic shift) makes 
this virus of special concern when investigating how the immune system can become 
harmful. Antigenic shift events usually presage the development of pandemic strains, as 
this process creates IAVs against which the population has no pre-existing immunity (71). 
1.3.2 Influenza A virus 
Influenza viruses are part of the family Orthomyxoviridae, which together comprise 7 
different genera and eight different species of negative-sense RNA viruses. Of these, IAV 
is by far the most relevant to public health, as Influenza A virus is a global pathogen, 
responsible for more than 500,000 deaths per year worldwide (72). Pandemic strains, which 
arise with alarming frequency, have the potential to cause even greater morbidity and 
mortality. The most famous of these pandemics, the 1918 Spanish Flu, killed an estimated 
50 million people worldwide, eclipsing the mortality arising from the first World War that 
it was cotemporaneous with (73). IAVs are named according to a standardized system that 
follows the format “species (if non-human)/location of isolation/isolate number/year of 
isolation/H and N subtype” (74). For example, strain A/Puerto Rico/8/1934/H1N1 (PR8) 
denotes a human IAV strain expressing H1 and N1, isolate number 8 retrieved from Puerto 
Rico in 1934. 
Clinically IAV infection is characterized by fever, malaise, cough and body aches that 
typically resolve in 7 to 10 days (75). Viral titres and shedding peak in the respiratory tract 
after about two days, with detectable virus shedding lasting an average of seven days after 
infection (76). IAV causes the most morbidity and mortality among the very young as well 
as elderly individuals, or those with complicating illnesses or immunosuppression (77). 
However, antigenically novel pandemic strains such as the 1918 Spanish Flu 
disproportionately affect or affected young, healthy individuals (78). The reason for this is 
partially attributable to a cytokine storm-like syndrome induced by overactivation of the 
immune system, which will be discussed later (79). 
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1.3.2.1 Structure and replication cycle 
Structurally, IAV is relatively simple when compared to larger viruses. Most particles of 
IAV are spherical and measure about 100 nm in diameter, though filamentous forms can 
be over 300 nm in length (74). The host-derived lipid envelope covering the virus is studded 
with hemaggluntinin (HA) and neuraminidase (NA) molecules, in addition to the matrix 
(M2) ion channel. Underneath the envelope is a layer of M1 protein, which encloses the 
virus replication machinery and single-stranded negative sense ribonucleic acid (ssRNA) 
genome. The whole genome codes for only 12 proteins, broken up over eight discrete 
segments (80). Within the viral core, the viral genomic RNA strands are coated with 
nucleoprotein (NP) molecules and associated with an RNA-dependent RNA polymerase. 
This polymerase is composed of three different proteins, two polymerase basic subunits 
(PB1 and PB2) as well as one polymerase acidic subunit (PA). The viral RNA, 
nucleoprotein and polymerase together make up what is referred to as the viral 
ribonucleoprotein complex (vRNP) (74). 
The viral replication cycle starts with binding of the outer HA protein to the sialic acid 
receptor on the host cell surface (81). Human IAV predominantly recognizes sialic acids 
bearing α-2,6 – linkages on galactose molecules, which are found in epithelial cells lining 
the trachea (82). Upon HA binding, the viral particle is internalized mainly via clathrin-
mediated endocytic pathways, whereupon it is trafficked from the early to the late 
endosome (83). The virus then gains entry into the host cell cytoplasm upon conformational 
changes in the viral HA protein induced by the low pH of the endosomal compartment, 
allowing fusion of the viral outer membrane with the host endosomal membrane. This 
genome release allows the vRNP complex to traffic to the nucleus, where mRNA encoding 
viral proteins are synthesized and viral genomic RNA is replicated. After nuclear export, 
the newly synthesized viral protein and genomic RNA travel to the host cell membrane 
where they are assembled into new viral particles. These particles then bud off from the 
infected cell, a process that relies on the sialidase activity of the NA protein to release these 
nascent viral particles from the host cell membrane (84). IAV subtype is classified 
according to the type of HA and NA molecules expressed on the surface. Currently, there 
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are 18 different HA and 11 different NA molecules circulating in the IAV population, 
though only a handful of these are found on strains that can infect humans (85). 
1.3.2.2 Pathogenesis 
IAV is transmitted through airborne particles that are formed as a result of coughing or 
sneezing of infected individuals (86, 87). Inhalation of these droplets allows the virus to 
reach the upper respiratory tract of a new host to initiate infection. The location of the 
epithelial cells in the airway that are infected by IAV influences the pathogenicity of a 
given flu strain. Seasonal IAV strains typically infect cells with α2,6-sialic acid linkages, 
which in humans are found predominantly in the upper respiratory tract (88). This usually 
causes a comparatively mild, self-limiting illness in most healthy individuals. However, 
highly pathogenic viruses such as avian H5N1 influenza strains preferentially infect cells 
with α2,3-sialic acid linkages, which in humans are found on type 2 pneumocytes deep in 
the lung (88). Infection of these cells can result in a serious, sometimes fatal viral 
pneumonia (89). In addition, the ability of the HA protein to be cleaved by host proteases 
also influences pathogenicity. In order to enter a cell, the HA molecule must first be cleaved 
into HA1 and HA2. Highly pathogenic strains of IAV can be cleaved by multiple different 
host proteases, increasing the likelihood that the virus will be able to enter the target cell 
(90). Ultimately, the main driver of pathogenesis that is directly attributable to the virus is 
its ability to induce apoptosis of infected cells. Much of this is attributable to the action of 
the PB1-F2 protein, which traffics to and disrupts the inner mitochondrial membrane and 
also induces the release of proinflammatory cytokines (91, 92).  
Host factors and the host immune response play a major role in the pathogenesis of IAV. 
Infection by IAV efficiently induces a type I IFN response as well as activation of nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB), which results in the 
production of large amounts of inflammatory cytokines and chemokines. In particular, the 
C-C motif chemokine ligand (CCL)5 and CCL2 recruit inflammatory macrophages to the 
alveoli, which in turn kill alveolar epithelial cells through a TNF-related apoptosis-
inducing ligand (TRAIL)-dependent mechanism (93). Highly pathogenic strains of IAV 
also induce a large influx of neutrophils that can also induce cellular damage, though the 
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role of these cells (pathogenic versus protective) is complicated by their important role in 
the control of viral titres (94, 95). In the most serious cases of viral pneumonia, the end 
result of the excessive epithelial cell damage and release of inflammatory cytokines is 
desquamation of the epithelial cell layers, pulmonary edema and the formation of hyaline 
membranes (96, 97). 
1.3.2.3 Antigenic shift and drift 
One of the defining features of IAV is its ability to undergo rapid antigenic change from 
year to year, allowing the virus to escape the action of neutralizing antibodies and 
necessitating the annual development of a new seasonal flu vaccine formulation. There are 
two major mechanisms underlying this antigenic change, known respectively as antigenic 
drift and antigenic shift.  Both are of concern when developing IAV-specific therapies, 
though large antigenic shifts remain the greater concern in terms of global health. 
Antigenic drift is defined as the accumulation of point mutations in regions of viral proteins 
that are recognized as epitopes by the immune system. In the case of IAV this antigenic 
shift is rapid enough to necessitate the development of a new seasonal flu vaccine every 
year for the northern and southern hemispheres, and extensive enough to describe IAV as 
a collection of quasispecies rather than a single definable virus (98). The main driver of 
antigenic drift is evolutionary selection pressure, in that viruses that escape antibody-
mediated neutralization survive and continue to spread between hosts (99). The mechanism 
underlying antigenic drift is the error-prone nature of the IAV RNA-dependent RNA 
polymerase, which creates a mutation 1×10-3 to 8×10-3 times per nucleotide per year (100). 
The polymerase also lacks exonuclease proofreading capability, therefore errors introduced 
during genomic replication are propagated rather than corrected (98). The antibody 
response to IAV is largely directed at epitopes in HA and NA. Thus, mutations in antigenic 
regions of these proteins that preserve their functional ability will create viruses that have 
a selective advantage.  
The process of antigenic shift relies on the fact that the genome of IAV is organized into 
eight separate segments. It requires the infection of a host cell by at least two different 
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IAVs such that the host cell acts as a “mixing vessel” for the genetic information from the 
two different strains (101). When the two different IAVs infect the same cell, the viral 
material from both strains is released into the cytosol and both viruses replicate their 
genetic material. However, since the RNA from both viruses is stored as discrete segments 
it is possible for the newly formed virions to package RNA segments that originated from 
both viruses. For example, three of the eight segments could be from virus A while five of 
the segments could be from virus B. This leads to the production of a strain of IAV that 
has the potential to be different antigenically from strains that had previously circulated in 
a given species. Swine often act as mixing vessels for human and avian viruses, as pigs 
express both α2,6-sialic acid linkages and α2,3 linkages on their airway epithelial cells, 
allowing infection by viruses from both species (101). Such recombined viruses, if they 
are able to efficiently infect human cells, can give rise to strains of IAV that are 
antigenically novel due to the presence of proteins originally confined to avian IAVs. 
Antigenic shifts are typically responsible for the rise of pandemic IAVs, as these shifted 
viruses have the potential to circulate among populations that have little to no pre-existing 
immunity (102, 103). 
1.4. Immune responses to influenza A virus 
Despite the ability of IAV to rapidly change its antigenic profile, the human immune 
system is capable of mounting robust immune responses to the virus. Immune responses to 
IAV occur first in the upper respiratory tract and lungs, followed later by the dispersal of 
adaptive memory cells to secondary lymphoid tissues such as the spleen and lymph nodes 
after resolution of infection. The primary response to IAV is largely mediated by innate 
immune cells and TCD8+, while control of secondary infection is achieved through the 
action of neutralizing antibodies (104).  
1.4.1 Innate immune responses to IAV 
The first adaptive immune effector cells reach the lungs 5 days after infection at the earliest 
(105). They require the help of the innate immune system for recruitment and activation; 
thus, the first line of host defense against IAV is the innate immune response. This consists 
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of a variety of physical barriers, antiviral proteins and cells that can act quickly in response 
to infection. 
 In humans, IAV infects the cells of the respiratory tract and, to a lesser extent, the lungs. 
Mucus that is naturally found in the airways is capable of trapping viral particles, while the 
ciliary beating action of airway epithelial cells transports mucus from the lungs to the upper 
respiratory tract (106). Human saliva also contains many chemical inhibitors that are 
capable of protecting against IAV, such as the defensins human neutrophil peptide (HNP) 
and histatin (107). H-filcolin can also bind IAV to prevent it from binding to sialic acid on 
lung epithelial cells, in addition to its complement-fixing ability (108). Deeper in the 
airways, other molecules such as surfactant protein-D (SP-D) have also been found to 
protect against IAV infection (109). Natural IgM is also present in the lungs and can fix 
complement upon binding to viral particles (110). 
The sialic acid-expressing airway epithelial cells also have innate defenses that are 
activated upon infection with IAV. They can release pre-formed IFNβ in response to 
infection, which results in the transcription of genes coding for antiviral proteins (111). In 
addition, PRRs expressed by epithelial cells are used to sense infection and activate 
antiviral defense pathways as well. TLR3 recognizes double-stranded RNA (dsRNA) 
produced during IAV replication, while TLR7 can recognize the ssRNA genome of IAV 
(112, 113). Retinoic acid-inducible gene I (RIG-I) and NOD-like receptors can also sense 
IAV infection and activate antiviral and inflammatory pathways (112, 114). In humans, the 
interferon-inducible MxA protein restricts viral transcription, and the absence of its mouse 
analog Mx1 in many laboratory mouse strains is responsible for the high susceptibility of 
these animals to IAV-induced morbidity and mortality (115, 116). 
Among the first innate immune cells to reach the lungs in response to IAV infection are 
neutrophils (117). They secrete many types of antiviral molecules including α-defensins, 
which can neutralize many strains of IAV (118). Neutrophils also phagocytose dead or 
dying cells, removing them from the airway while simultaneously capturing viral antigen 
for presentation (119). This allows neutrophils to act as APCs for the cells of the adaptive 
arm of the immune system (120). After being recruited to the lung by the release of IL-15, 
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NK cells also play an important role in the control of viral titre (121). However, the key 
immune cells in the innate response to IAV are the alveolar macrophages. They are 
essential for the control of viral replication in the lungs through their phagocytic activity 
and early secretion of cytokines and chemokines (122, 123, 124). They are the major 
producers of granulocyte-macrophage colony-stimulating factor (GM-CSF) upon IAV 
infection, which is necessary for the recruitment of DCs and downstream adaptive immune 
responses (125). This critical role in orchestrating the immune response to IAV also means 
that dysfunctional alveolar macrophages have the potential to be highly pathogenic, as will 
be discussed in later sections of this thesis. 
1.4.2 Adaptive immune responses to IAV 
Clearance of IAV infection usually relies on an effective adaptive immune response. 
Optimal virus clearance is characterized by vigorous humoral and cell-mediated responses, 
and the generation of memory cells specific for IAV can effectively prevent re-infection 
by the same virus many years later. 
1.4.2.1 Humoral responses 
Infection with IAV results in production of IgG, IgM and IgA isotype antibodies. 
Typically, the antibodies that confer protection against re-infection are of the IgG isotype 
and are directed against the HA and NA proteins on the surface of IAV (126). The 
prevention of re-infection is largely attributable to the neutralization of the virus mediated 
by the binding of Ab to HA, and high serum titres of HA-specific IgG are an excellent 
correlate of protection against infection with antigenically similar IAV strains (127). The 
HA molecule on the surface of IAV exists as a trimer, with each subunit consisting of a 
stalk region ending in a globular head (128). Binding of Ab to this head domain prevents 
the HA molecule from binding to the sialic acid receptor on the surface of epithelial cells 
in the respiratory tract, preventing virus entry into the cell. Abs against the stalk domain 
are also formed, but these are subdominant to the head domain antibodies and do not 
typically prevent viral entry unless the virus is present in very high titres (129). NA-specific 
IgG antibodies are also present after IAV infection, though these likely do not protect 
19 
 
against initial infection (130). The function of NA is to cleave sialic acid on the surface of 
the host cell, allowing newly-formed viral particles to detach from the cell membrane. NA-
specific Abs block this sialidase activity, thereby limiting the spread of the virus to 
uninfected cells. Both HA and NA-specific Abs also have the capacity to initiate antibody-
dependent cell-mediated cytotoxicity (ADCC) by NK cells, which can further contribute 
to virus clearance by removing IAV-infected cells (131). Ab responses against the M2 and 
NP proteins have also been detected, though these tend to have low titres and constitute a 
mode of protection that is incompletely understood (132, 133). 
IgM antibodies are present during primary infection with IAV and almost entirely absent 
during secondary infection due to B cell class-switching to other isotypes. IAV-specific 
IgM can neutralize IAV by binding the viral particles and by activation of the complement 
pathway (134). The presence of serum IgA seems to be indicative of recent IAV infection, 
while IgA that is produced in the respiratory mucosa can confer local protection against 
viral infection (135). While IgA and IgM can both confer some degree of protection against 
IAV infection and morbidity, IgG is the crucial antibody isotype for control of both primary 
and secondary infection (136). 
1.4.2.2 Cell-mediated responses 
The involvement of CD4+ T cells in IAV-specific immunity is largely to provide help to 
macrophages and IAV-specific B cells. A balance must be achieved with regards to the 
induction of Th2 versus the Th1 responses (production of IFNγ) that are necessary for the 
formation of memory CD8+ T cells (137). The typical CD4+ T cell response to IAV is 
predominantly Th1-skewed, though this has to be kept under tight control by T regulatory 
(Treg) cells to prevent immunopathology (138, 139). The presence of long-lived CD4+ 
memory T cells in the lung has also been correlated with protection against IAV infection 
(140). Evidence has also suggested a role for cytolytic CD4+ T cells in the IAV-infected 
lungs as contributors to IAV-specific immunity, especially in the context of heterosubtypic 
infection (141). T regulatory (Treg) cells also play a role in the control of immune 
responses to IAV. They are necessary to prevent excessive inflammatory responses and 
subsequent tissue damage during the response to IAV (139).  
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TCD8+ are important for the control of primary infection with IAV (142). They are 
recruited to the lungs after activation in the lymphoid tissues where their function is to 
eliminate virus-infected cells. They typically do so via the perforin/granzyme pathway, 
though gene knockout approaches have shown that CD8+ cytotoxic T cells can kill IAV-
infected cells through other pathways if the perforin/granzyme pathway is unavailable 
(143). TCD8+ can recognize epitopes derived from the internal proteins of IAV, which are 
more likely to be conserved in comparison with exterior proteins that are subject to 
selection pressure to avoid neutralization by Abs (144).  However, the role of CD8+ T cell-
mediated protection in humans has been difficult to study due to the dominant role of Ab 
responses in protection against IAV infection. Recent evidence from individuals infected 
during the H1N1 pandemic showed that the presence of heterosubtypic CD8+ T cells was 
correlated with lower lung viral titres (145). In addition, a study of severe H7N9 infection 
cases requiring hospitalization showed that early heterosubtypic CD8+ T cell responses 
were correlated with increased survival and earlier discharge from hospital (146).  
1.4.3 Immune evasion mechanisms 
As discussed earlier, antigenic drift and shift result in the evolution of viruses that avoid 
neutralization by IAV-specific antibodies. In addition to changing its antigenic profile, IAV 
has evolved numerous ways to evade and interfere with the host immune response despite 
its relatively small complement of proteins (12 in total)  (80). The IAV protein with the 
most prominent role in control of the host immune response is non-structural protein 1 
(NS1). This protein can interfere directly with innate immune sensors such as RIG-I and 
protein kinase R (PKR), preventing them from performing their function as sensors of viral 
RNA (147, 148). NS1 can also interfere with 3’ polyadenylation of host mRNA as well as 
its export out of the nucleus, which reduces the capacity of the host cell to express antiviral 
proteins (149, 150). In addition, the mere presence of replicating IAV within the host cell 
creates competition for cellular resources, further hindering the ability of the cell to mount 
an antiviral response. The viral RNA polymerase steals 5’ caps from processed host 
mRNAs to attach to viral RNA destined for translation by the host ribosome, which 
decreases the translation of host proteins (151). The PB1-F2 protein, in addition to its role 
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in promoting cell death, has been shown to interact with IKKb to prevent nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) signalling (152).  
1.4.4 Vaccination against influenza A virus 
Though antiviral drugs such as the neuraminidase inhibitors oseltamivir and zanamivir 
continue to be used to treat IAV infection, a more attractive strategy for the control of IAV 
is through the use of vaccination. Neutralizing antibody responses are typically directed 
against the globular head domain of the HA protein on the surface of IAV (128). This 
interferes with the binding of HA to sialic acid receptors on the surface of the target cell, 
preventing viral entry and infection. Both serum IgG and mucosal IgA responses have 
proven efficacious in this capacity (136). Antibody responses directed against NA can also 
limit the spread of IAV by preventing the nascent virus from leaving the host cell 
membrane (130). Current seasonal IAV vaccines are formulated against the predominant 
seasonal H3N2 strain, an H1N1 strain and one influenza B strain (153). They induce strong 
antibody responses against HA, providing excellent protection if there is a good match 
between the vaccine strains and the naturally circulating IAV. However, this strategy relies 
on the accurate prediction of which flu strains will be circulating in the coming year, an 
approach that is often imperfect given the potential for antigenic shift events to occur 
without warning. To get around this problem there has been a great deal of interest in the 
generation of IAV vaccines that produce antibody responses against the highly conserved 
stalk domain of the HA protein (154). Stalk-specific antibodies are naturally present after 
vaccination with whole, split-virion or HA-based vaccines, but they are subdominant to the 
head antibodies (155). Therefore, only a precious little is known about their ability to 
protect against IAV infection. Several groups are currently working on this problem, and 
there have emerged several promising vaccine candidates that have been shown to confer 
protection in mouse models of IAV infection (156, 157, 158, 159). 
In addition to vaccines that rely on antibody-mediated protection, there exists potential for 
the use of CD8+ T cell-based strategies in the context of therapeutic vaccination against 
IAV. Though such a vaccine would be less useful in preventing infection (CD8+ T cells by 
definition eliminate cells that are already infected), they could be very useful for the 
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treatment of primary IAV infection. TCD8+ recognize epitopes derived from the interior 
of the virus as well as the exterior, and thus could potentially eliminate viruses that have 
escaped antibody-mediated neutralization (160). The interior proteins of IAV are also 
subject to less intensive selection pressure than HA and NA, and are therefore more likely 
to be highly conserved (161). This opens up the possibility of using CD8+ T cell vaccination 
strategies to confer heterosubtypic immunity to current as well as future IAV infections. 
One potential barrier to effective humoral and cellular vaccine strategies against IAV is the 
phenomenon of “original antigenic sin” (OAS). This was first noticed in the context of 
antibody responses to IAV, in that people who had been vaccinated against a given strain 
of IAV only produced Abs against that particular strain, even after vaccination with highly 
immunogenic epitopes from other viral variants (162, 163). OAS is thought to arise because 
antibodies and CD8+ memory T cells that recognize the original virus mask any response 
of naive adaptive cells specific for epitopes from the new virus (164). Vaccination with a 
virus that shares no cross-reactive epitopes is one way to overcome OAS, though this is 
not a realistic strategy for seasonal influenza given the potential for year-to-year antigenic 
similarity between viruses. Other strategies to mitigate OAS include delivery of high 
antigen loads and the inclusion of B cell adjuvants to boost responses to the new virus (165, 
166) Any successful IAV vaccine will have to take the OAS into account, especially when 
dealing with highly heterogeneous human populations. 
1.5. Animal models of influenza A virus infection and 
vaccination 
Data on IAV-associated morbidity and immunity in humans is derived from cases of 
natural infection with seasonal and pandemic IAV, as well as limited volunteer studies that 
have utilized low doses of flu and attenuated strains (167, 168, 169, 170). For these reasons 
a number of different animal models have been developed to study the course of IAV 
infection as well as the efficacy of vaccination and other therapies to prevent and treat IAV 
infections.  
1.5.1 Mice  
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Mice are far and away the most popular model for IAV, despite the fact that influenza is 
not a natural mouse pathogen. There are many inbred strains, knockouts, and species-
specific regents tailored to the study of IAV infection in this model. However, mice are not 
susceptible to infection with human-adapted IAV strains, and even after infection they are 
not typically capable of transmitting the virus to other mice by contact or by aerosol (171, 
172). The airways of mice typically feature α2,3-sialic acid linkages, while human IAV 
has adapted to recognize α2,6 linkages (173, 174). Therefore, the study of IAV in mice 
typically relies on the use of mouse-adapted IAV strains such as A/Puerto Rico/8/1934 
H1N1 (PR8), which are highly lethal in inbred laboratory strains due to the lack of a 
functional Mx1 protein in these animals (175, 176).  
In addition to differences in viral tropism, IAV infection in mice results in a different 
constellation of symptoms than those observed in humans. Instead of developing fever, 
IAV-infected mice are typically hypothermic and display a hunched posture, ruffled fur 
and weight loss (177). They don’t develop sneezing or coughing, but examination of the 
lung tissue of infected mice after euthanasia reveals tissue destruction as well as the 
infiltration of macrophages and neutrophils (178). Despite the differences between humans 
and mice in terms of viral tropism and pathology, mice remain a very useful model for 
studying influenza due to the comparatively low cost of husbandry and wide availability 
of reagents (177). 
1.5.2 Ferrets 
Ferrets are considered a good model for IAV infection because they are one of the few 
animals that display human-like symptoms when infected with human-adapted IAV (179, 
180). Infection by IAV in ferrets manifests as an upper respiratory tract infection, 
accompanied by sneezing, fever, nasal congestion, weight loss and lethargy (180). 
However, a notable difference between the course of disease in ferrets as compared to 
humans is the tendency of some virus strains, notably highly pathogenic Asian influenza 
(HPAI) and H5N1, to infiltrate the central nervous system and cause virus-induced 
encephalitis (181).  In addition to being naturally susceptible to infection with human IAV, 
they can also be infected with influenza viruses originating from birds and swine (182, 
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183). Transmission of infection between ferrets also closely parallels what is observed in 
human populations, as IAV can be spread between animals by direct contact and aerosols 
(184). This makes ferrets a suitable model for IAV transmission as well as pathogenesis. 
The main drawback associated with studying IAV infection using a ferret model is the cost. 
Ferrets are larger than mice and thus require more space for housing (177). In addition, the 
specialized nature of the ferret model has resulted in a relative dearth of reagents, such as 
specific monoclonal antibodies, when compared to more commonly used animal models 
such as mice. The availability of inbred and genetically engineered strains is also limited 
when compared to the options available for rodent models. Nevertheless, the close 
similarities between the course of disease in ferrets and humans make these animals an 
excellent choice for studies of IAV transmission and pathogenesis.  
1.5.3 Guinea pigs 
Guinea pigs are also able to be naturally infected with human-adapted strains of IAV, 
though viral titres in the lungs and airways tend to be lower than those found in humans 
and ferrets (172). It is also possible for the virus to be transmitted between animals via 
direct contact or aerosol (185). Guinea pigs are also easier and less expensive to house than 
ferrets, though the model still suffers from a relative lack of commercial species-specific 
reagents. The main drawback of the guinea pig model is the lack of symptoms associated 
with IAV infection (186, 187). The dose of IAV needed to cause mortality in guinea pigs 
in much higher than that in the ferret model, and the overt signs of disease are confined to 
very limited weight loss, nasal mucus production and listlessness, even for highly 
pathogenic IAV strains (187). However, histopathological changes as a result of infection 
can be observed in the lungs, as well as immune cell infiltration (187). The lung 
architecture of guinea pigs is also more similar to humans than other animal models (188).  
1.5.4 Nonhuman primates 
The obvious attraction of a nonhuman primate (NHP) model is the relatively close genetic 
and physical similarities between NHPs and humans. Macaques are the preferred NHP 
model for influenza studies, largely because of their smaller size and less extensive housing 
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requirements as compared to other primates such as chimpanzees (177). NHPs can be 
infected with unadapted human strains of IAV, resulting in similar morbidity and viral 
titres (189, 190, 191). Animals that are infected with IAV display the typical symptoms of 
viral pneumonia in humans, such as fever, cough, and lethargy (189). In cases where 
macaques were euthanized after infection high viral titres were found in the lungs, as well 
as pathology typical of IAV pneumonia in humans (189, 192). However, IAV studies using 
NHPs tend to be rare due to the cost and ethical concerns surrounding research using these 
animals. 
1.6. CD8+ T cell responses to influenza A virus 
Though the study of long-term immunity to IAV is mostly focussed on the generation of 
memory B cells and enhancement of neutralizing antibody responses, TCD8+ remain an 
important cell type in anti-influenza immunity. Their activation and effector activities are 
important for the primary response to novel IAV strains, against which neutralizing 
antibodies have not had the time to form. TCD8+ also recognize epitopes derived from the 
highly conserved interior of the virus, making them an attractive therapeutic target for the 
control of heterosubtypic infections. 
1.6.1 Naive IAV-specific CD8+ T cells 
IAV infection begins when the cells of the upper respiratory tract come into contact with 
virus delivered on airborne droplets. The infection is usually confined to this area but can 
spread to the lower respiratory tract and lungs, resulting in a more severe disease (192). 
Naive TCD8+ that are specific for IAV reside in the secondary lymphoid organs such as 
the spleen and lymph node after exit from the thymus. They remain in these tissues and in 
the circulation until activation by DCs displaying IAV-derived peptide epitopes. Human 
studies of natural infections have demonstrated that the number of naive IAV-specific T 
cells is negatively correlated with symptom severity (145). In addition, early and robust 
TCD8+ responses ostensibly enabled by higher numbers of IAV-specific CD8+ cytotoxic 
T lymphocyte (CTL) precursors were associated with decreased morbidity and mortality 
after primary H7N9 infection (193). 
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1.6.2 Phases of the TCD8+ response to IAV 
CD8+ T cells are part of the adaptive arm of immunity, and thus require a few days in order 
to become fully activated and able to traffic to the site of infection in response to 
inflammatory signals (194). Once in the lungs effector TCD8+ quickly search out IAV-
infected cells and destroy them, before undergoing deletion. At the same time, memory 
cells specific for IAV epitopes are generated. Memory precursor cells that do not express 
the interleukin-7 receptor (IL-7R) undergo cell death, while IL-7R+ cells survive to form a 
pool of long-lived memory cells (195). These memory cells are then available for re-
activation upon re-infection years after the initial event, whereupon they rapidly proliferate 
and differentiate into a new batch of effectors. Each phase of this process is covered in 
more detail in the following sections. 
1.6.2.1 Priming of naive TCD8+ 
Antigen presentation to naive T cells in the lymph nodes draining the lung is largely 
mediated by DCs. In the infected lung, DCs can acquire IAV-derived antigen through 
cross-presentation pathways after phagocytosis of dead or dying lung epithelial cells. In 
addition, there is also some degree of antigen transfer between migratory DCs from the 
lung to resident lymph node DCs, which then present the Ag to naive TCD8+ (196). 
Infection of lung migratory DCs directly by IAV does not often occur, as they typically are 
protected by increased type I IFN signalling activity (197). Upon antigen acquisition the 
mature DC up-regulates CCR7 expression on their surface, which allows them to travel to 
the lymph node (198). This wave of DC antigen capture and migration from the lung to the 
LN takes place in the first 4 days after IAV infection (198). In mouse models, deletion of 
CD103+ DCs, the subset that plays the greatest role in cross-priming during IAV infection, 
causes delayed primary TCD8+ responses and viral clearance (199). In mice, the vast 
majority of naive T cell priming occurs in the draining regional lymph nodes, with a smaller 
population undergoing priming in the spleen (200). The activation of a naive T cell requires 
three signals: Recognition of the peptide/MHC complex through the TCR, costimulation 
through CD28 by CD80/86 on the APC, and release of appropriate cytokines such as IL-2 
(20363604). If any one of these signals is missing the naive TCD8+ will likely die of 
27 
 
apoptosis or become anergic to any further TCR signalling. During this priming step 
TCD4+ cell help is needed for generating optimal TCD8+ memory responses, but is not 
essential for the primary response (201, 202). The naive T cells quickly proliferate, 
expanding in number at least 10-fold before starting to migrate out of the lymph node to 
other sites by day 5 after infection by selective loss of CD62L (203).   
Once activated, the CD8+ T cells exit the lymph node and travel to the lung. This is 
achieved primarily through the expression of CD11a on the CD8+ T cells, which bind the 
ligand intercellular adhesion molecule-1 (ICAM-1) on the surface of the lung epithelial 
cells (204). This allows CD8+ T cells that have entered the circulation to be recruited 
specifically to the lung tissue, with additional roles being played by LFA-1 expression and 
CCR4 expression on the T cells themselves (204, 205). Entry into the airway from the 
circulation is achieved in response to IL-15, which in itself is an inducer of CD11a 
expression (206). IL-15 expression is induced by type I IFN production, thus helping the 
circulating CD8+ T cells to end up in the right location (207). 
1.6.2.2 TCD8+ effector function 
The main function of an activated, antigen-specific TCD8+ is to kill host cells displaying 
their cognate peptide antigen in the context of MHC I. This signals to the TCD8+ that the 
host cell has become infected by a virus and as such it needs to be eliminated to prevent 
propagating the infection. TCD8+ can kill their targets using one of three (technically four) 
ways. The most prominent pathway used by TCD8+ in response to detection of an IAV-
infected cell is the perforin/granzyme pathway, in which perforin molecules produced by 
the CD8+ T cells get inserted into the membrane of the target cell, forming a pore on its 
surface (143). The CD8+ T cell then releases granzymes through the pore and into the 
target cell, resulting in the activation of intracellular caspases and the induction of 
apoptosis. CD8+ T cells also express Fas ligand (FasL) on their surface, which can bind 
Fas on the infected target cell to induce apoptosis (208, 209). The third killing mechanism, 
expression of TRAIL and its engagement with TRAIL-DR on the target cell surface, works 
on a similar principle. Both induce intracellular signalling that converge on the caspase 
pathway to induce the formation of an apoptosome and subsequently induce cell death 
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(210). Effector CD8+ T cells are major producers of IFNγ and TNFα, both of which 
contribute to anti-IAV responses (209). IFNγ, in addition to its stimulatory effect on other 
TCD8+, also enhances the class-switching of B cells (211). TNFα production is technically 
the fourth method of killing by activated TCD8+, but it is non-specific and doesn’t typically 
require cell-to-cell contact to exert its effects (212). Binding of TNFα to the TNF receptor 
on the target cell surface will induce apoptosis, though excessive TNFα production is 
associated with immunopathology (213). Effector TCD8+ responding to IAV infection 
show great flexibility in their choice of pathway when lysing target cells. Mouse studies 
have shown that genetic knockout of the granzyme A/B pathway does not lead to increased 
morbidity as a result of IAV infection in a mouse model (214). The same effect was 
observed for the genetic ablation of killing by the Fas/FasL pathway, however knockout of 
both at the same time resulted in a lethal infection (143). Another group has shown that 
interfering with the TRAIL pathway for killing resulted in greater morbidity and higher 
viral loads (215). Effector CD8+ T cells that can produce more than one cytokine at a time, 
namely IL-2, IFNγ and TNFα, are generally more protective than cells that produce only 
one or two of the cytokines (216). 
1.6.2.3 Recall and memory responses to IAV 
Successful resolution of the primary infection results in the contraction of the CD8+ effector 
T cell population and generation of a long-lived pool of IAV-specific memory TCD8+. 
However, the longevity of IAV-specific memory cells in humans is unclear. One study 
tracking the cytotoxic potential of IAV-specific TCD8+ showed that by 5 years the ability 
of these cells to kill their target in an ex vivo 51Cr- release assay was diminished (217). 
However, other studies merely looking for the presence of memory IAV-specific TCD8+ 
by tetramer staining could locate them for as long as 13 years after initial infection (218). 
Indeed, cases of natural infection with the 2009 H1N1 viruses showed that older adults 
who had pre-existing cross-specific immunity from earlier flu infections had lower 
symptom scores than those who did not have cross-reactive TCD8+ (145).  
In response to IAV infection in the lungs, memory TCD8+ that reside predominantly within 
the lung tissue and draining lymph nodes are re-activated (219). The number of memory 
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cells for a given antigen is markedly higher than the number of naive CD8+ T cells that 
had existed before antigen contact, so this expansion happens much more quickly than the 
expansion of naive CD8+ T cells (220, 221). The population of cells that makes up the 
memory CD8+ T cell compartment is heterogeneous; it can be roughly divided into central 
memory and effector memory subsets. Central memory cells express CD127, CD45RO and 
CCR7, with CCR7 expression acting to keep them in the lymph node (222). This second 
category, the effector memory CD8+ T cells, express CCR3 and CCR5 that allow them to 
respond to inflammatory signals in the lung tissue. Once the effector memory cells are 
activated they proliferate and give rise to effector CD8+ T cells, which then seek out and 
lyse target cells displaying their cognate antigen. In terms of viral clearance memory CD8+ 
T cell responses are dispensable given the presence of neutralizing Ab responses, but in 
the case of incomplete or absent neutralization, they can reduce symptom severity and 
provide some degree of heterosubtypic protection (126, 223). 
1.6.3 Immunodominance in CD8+ T cell responses to IAV 
Immunodominance (ID) describes the propensity of T cell responses to be directed against 
only one or few peptides rather than being distributed evenly amongst the multiplicity of 
different epitopes that could be recognized from a given pathogen. The reasons for the 
formation of ID hierarchies, and why some epitopes produce measurable T cell responses 
while others fail to do so vary depending on the system being investigated. In the case of 
human IAV infection in HLA-A2+ individuals, the vast majority of TCD8+ responding to 
infection are directed against M158-66 (224). In addition, almost all M158-specific TCD8
+ 
have a Vβ17+ TCR across most individuals studied (225). Structural analyses have shown 
this is due to this particular TCR makeup being very good at binding M1 point mutants 
with relatively high affinity, meaning that M1 can mutate without losing the ability to bind 
M158 (226). In addition, upon TCR binding, the M1 peptide is squeezed into a relatively 
flat conformation that is easily recognizable by the Vβ17+ TCR regardless of point 
mutations (227). For the IAV-specific TCD8+ response in mice, ID hierarchies arise due to 
the relative abundance of proteins from which dominant peptides are derived (as is the case 
with NP) and due to the avidity with which some peptides bind MHC and TCR. This is the 
case with the co-dominant NP336-374 response in B6 mice, as the NP336 peptide is able to 
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bind its cognate TCR with high avidity, out-competing other T cell clones despite similar 
precursor numbers. Immunodominant responses are not always immunoprotective, as these 
responses are under stronger selection pressure and thus may be more susceptible to 
mutation (228, 229). In this case it is desirable to design therapies that can boost 
subdominant responses in order to deal with possible escape mutants within a viral 
population.  
1.7 Coinfection with IAV and Gram-positive bacteria 
Clinically, opportunistic bacterial infections in the IAV-infected lung are a significant 
problem. Pulmonary complications subsequent to IAV infection have been noted as far 
back as the 1918 Spanish Flu pandemic, and Gram-positive bacteria such as S. pneumoniae 
and S.aureus continue to be major complicating pathogens in secondary bacterial 
pneumonias (230). As well, coinfections between Gram-positive bacteria and IAV have 
the opportunity to occur during the immunosuppressive phase of recovery after TSS (231) 
or microbial sepsis (232, 233).  
1.7.1 IAV infection of septic and toxic shock patients 
It has previously been noted in the medical literature that survivors of sepsis and TSS have 
an elevated risk of dying from non-septic illnesses that lasts for years after recovery (234, 
235). In addition, patients recovering from sepsis have an increased susceptibility to 
secondary infection and increased odds of latent viral reactivation, both of which can prove 
deadly (236). The mechanism underlying this increased susceptibility to illness and death 
has been a subject of investigation using many different models of sepsis followed by 
infection. Badovinac et. al. have observed that mice with sepsis induced by cecal ligation 
and puncture (CLP) that were allowed to recover had an altered  TCD8+ repertoire that 
lasted for months after recovery from sepsis (237). More specifically, they found naive 
TCD8+ that were specific for lymphocytic choriomeningitis virus (LCMV) were reduced 
in number after recovery from CLP. The relative dearth of naive precursors in the post-
CLP mice resulted in a smaller TCD8+ response to subsequent LCMV infection. The same 
group in a follow-up study also noted that TCD8+ that were capable of responding to 
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infection were more easily exhausted (as determined by expression of exhaustion markers 
and reduced cytokine expression by Ag-specific T cells) than cells from mice that had not 
been subjected to CLP (238). Human studies addressing the same problem have revealed 
that T cells in septic patients down-regulate pro-survival factors such as Bcl-2 and display 
increased apoptosis (239, 240). Epidemiological studies have also shown that sepsis 
survivors are much more likely than the average population to die from infectious illnesses 
caused by a variety of bacteria, fungi and viruses (241). Though data regarding the co-
occurrence of IAV infection and TSS is more difficult to find (likely due to the rarity of 
TSS), cases have been reported in which bacterial TSS is noted as a complication of IAV 
infection (242, 243). In both of these cases bacterial colonization of the respiratory tract 
during IAV infection acted as the trigger for TSS. Another report shows this happening on 
a larger scale, with the outbreak of IAV among patients in a psychiatric facility being 
complicated by concomitant bacterial TSS (244). 
1.7.2 Secondary bacterial pneumonia complicating IAV 
infection 
Secondary bacterial pneumonia is a well-known complication of IAV infection with a long 
clinical history. During the 1918 Spanish flu pandemic up to 95% of all deaths had some 
bacterial involvement, typically S. pneumoniae (245). This pattern was repeated during the 
1957 and 1968 flu pandemics, where autopsies revealed that close to 75% of those who 
died had a form of bacterial pneumonia, though by this time the bacteria that were 
predominantly found consisted of P. aeruginosa and S. aureus (246, 247). In the latest flu 
pandemic, the 2009 H1N1 swine flu outbreak, roughly 30% of all fatal cases had bacterial 
involvement despite increased usage of antibiotics. Most cases of bacterial coinfection 
were due to S. pneumoniae, S. pyogenes or S. aureus depending on geographical location 
(248, 249). 
There are many ways in which IAV and bacteria in the infected lungs can act 
synergistically to enhance infection and replication. The most obvious way is through the 
direct damage IAV inflicts upon the respiratory epithelium, which liberates nutrients and 
creates more surface area for bacterial attachment (250). This direct damage can be 
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augmented by the expression of especially virulent variants of the PB1-F2 protein, which 
causes increased cytotoxicity relative to the wildtype protein (251). This has been shown 
experimentally in mice; a study by Iverson et. al. using superinfection with S. aureus after 
IAV infection showed that mice infected with PB1-F2 deletion strains had less mortality 
than those infected with WT virus (252). In addition, damage caused by IAV infection can 
result in the destruction of ciliated airway cells, which hampers the ability of the airway to 
mechanically remove debris and bacteria (253). The NA activity of IAV after viral exit can 
also cause the exposure of novel binding sites for bacteria by cleaving sialic acid from the 
cell surface (254). Changes in the activation state of epithelial cells in response to 
inflammation can also cause the expression of different cell surface proteins that bacteria 
can use as sites of attachment (255). A more subtle form of synergy between bacteria and 
IAV occurs due to the fact that immune skewing towards an antiviral response hinders any 
concomitant action against invading bacteria (256). Efficient clearance of bacteria from the 
lungs requires a Th17 response, which is characterized by production of IL-17 by TCD4+ 
and is inhibited by type I IFN signalling induced by IAV infection (257). Repression of 
this response results in reduced TLR ligand signalling and subsequent poor recruitment of 
neutrophils to the lung in response to bacterial infection (258). IAV infection also causes 
alveolar macrophages to down-regulate the expression of macrophage receptor with 
collagenous structure (MARCO), a key scavenger receptor necessary for the innate 
recognition of bacterial infection (259, 260). 
1.7.3 Superantigens and IAV 
The likelihood of IAV infection being complicated by concomitant bacterial invasion (and 
vice versa) raises the question of why these coinfections occur with such frequency. 
Bacterial species such as S. aureus and S. pyogenes both encode SAgs that have significant 
effects on immune cells (261). Bacterial superantigens are noted for their ability to induce 
proliferation of both CD4+ and CD8+ T cells bearing certain Vβ regions as a part of their 
TCR, which is thought to be followed by deletion or anergy of the responding T cells. The 
CD8+ T cell responses directed against immunodominant IAV epitopes in both BALB/c 
mice and in HLA-A2+ humans utilize Vβ regions that are known to bind certain SAgs (262, 
263). It stands to reason that bacterial SAgs may hinder the T cell-mediated response to 
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IAV causing the deletion or anergy of T cell clones that are needed for effective adaptive 
immunity to IAV. 
The evidence supporting the idea that SAg administration results in proliferation followed 
by anergy or death largely stems from experiments using in vivo administration of SEB 
followed by in vitro restimulation of T cells. These observations consisted of a lack of IL-
2 production and Vβ8+ T cell proliferation following the in vitro re-exposure to the same 
SAg (54, 264). This lack of proliferation could not be rescued by exogenous addition of 
IL-2, and was found to persist for at least a month after contact with SEB. In addition to 
inducing anergy in bulk primary T cells, antigen-specific memory T cells were found to 
display an anergic phenotype after SEB administration. In one paper, mice with memory 
cells specific for the model antigen  keyhole limpet hemocyanin (KLH) were treated with 
SEB and the ability of these CD4+ cells to provide help to B cells for antibody production 
was assessed (265). When cultured with B cells, the memory CD4+ T cells from SEB-
treated mice were less able to stimulate KLH-specific Ab production.  Another group later 
reported a similar CD4+ T cell response to SEB in mice transgenic for an ovalbumin 
(OVA)-specific Vβ8.2+ TCR (266). Notably, the bulk of the literature concerning T cell 
anergy in response to SEB has focussed on CD4+ T cell responses rather than CD8+ T cells. 
Previous studies examined the effect of SEB on cell-mediated responses to IAV. In 1996, 
Zhang et. al. (267) noted that administration of sub-lethal amounts of SEB to mice infected 
with a sub-lethal dose of IAV induced mortality that was dependent on the relative timing 
of infection and SEB administration. Maximum mortality occurred when the mice were 
given SEB 7 days after IAV infection, which corresponds to the peak of the primary CD8+ 
T cell response to IAV. They further noted that this mortality was dependent on the 
presence of SEB-reactive T cells; mice that had their Vβ8+ T cell population experimentally 
depleted on day 5 after infection (2 days before SEB administration) were significantly less 
likely to die than control mice. The enhanced mortality was linked to the production of 
TNFα and IFNγ; administration of these cytokines in place of SEB partially recapitulated 
the observed phenotype. Four years later, the same lab published a study examining the 
effect of SEB and the related SAg SEA on the primary and recall responses to IAV 
infection (268), expanding on the findings reported in the previous paper. Their 
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experiments utilized B6 mice, whose CD8+ T cell response to IAV is characterized by the 
co-dominance of NP366- and PA224-specific CD8
+ T cells. Detection of NP366-specific cells 
in the bronchoalveolar lavage (BAL) fluid and other tissues was accomplished using an 
MHC I tetramer. These NP366-specific CD8
+ T cells are known to be Vβ8.3+, which are 
sensitive to SEB but not to SEA (269). On day 7 after intranasal IAV infection the mice 
were given an intraperitoneal injection of SEB, resulting in the expansion of NP366-specific 
cells in the peripheral blood and BAL. The number of these cells had returned to baseline 
by 8 days after SEB administration. Neither SEB nor SEA caused a change in the 
percentage of NP366-specific cells, though cytotoxic killing of IAV-infected target cells as 
measured by 51Cr-release assay was elevated for cells recovered from the BAL for both 
SAgs up to two days after injection. Curiously, viral clearance from the airways for both 
SEA- and SEB-treated mice was delayed as compared to mice injected with vehicle. In 
addition, there appeared to be no effect of SEB injected during the primary response on the 
secondary response to intranasal IAV challenge as measured by the relative expansion of 
Vβ8.3+ NP366-specific cells.  
Subsequent papers examined the effect of SEB in memory responses to IAV. In particular, 
a 1997 paper by Coppola et. al. reported that far from inducing anergy, SEB actually 
reactivated IAV-specific CD8+ T cells (270). The authors used a model that involved 
intranasal infection of CBA/CaJ mice as well as mice on the same background bearing a 
TCR transgene for Vβ8.1. The mice were given time to recover from the infection and 
develop a stable memory repertoire, at which point the mice were injected with SEB i.p. 
and had their splenocytes harvested. Using a chromium release assay utilizing L929 cells 
infected with IAV, they found that CD8+ T cell-enriched samples induced massive IAV-
specific killing after in vivo or in vitro SEB stimulation. They further showed that this 
killing was partially TCR-dependent as the mice bearing the SEB-reactive transgenic TCR 
had greater specific killing at comparable effector:target ratios. Though not directly shown, 
the authors also asserted that the IAV-specific effector CD8+ T cells proliferate and secrete 
IL-2. However, a later paper published by the same lab highlighted a different interaction 
between SAgs and IAV-specific memory CD8+ T cells (271). In this paper, the authors 
used B6 mice that had been intranasally infected with IAV, as the immunodominant NP366-
specific response is known to mainly consist of cells bearing Vβ8.3+ TCRs in this strain. 
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SEB was administered subcutaneously via an implanted pump, which gradually released 
small amounts of SEB over the course of 7 days. They then used NP366-specific tetramer 
to assess the frequency of epitope-specific cells in the BAL fluid after secondary exposure 
to IAV. They found that Vβ8.3+ NP366- specific cells were decreased in the SEB-treated 
mice, and that bulk BAL cells from the SEB-treated mice were less effective at lysing 
NP366-pulsed L929 target cells. Assessment of viral titres in PBS- versus SEB-treated mice 
after secondary infection showed no defect in clearance in the SEB-treated mice, though 
experiments with thymectomized animals showed that naive T cells from the thymus were 
responsible for compensating for the defective memory response.  
Overall, the literature paints a picture of influenza-specific TCD4+ anergy induced by SEB, 
with the effect of SEB on the TCD8+ response being less clear (Fig. 1). Most studies that 
touch on the effect of SAgs on TCD8+ utilize a two-hit model of SAg administration rather 
than following the effect of one exposure to SAg, or focus on bulk polyclonal TCD8+ 
reponses. Interpretation of the biological role of SAg on antigen-specific TCD8+ responses 
is further complicated by examination of only the TCD8+ population specific for the 
immunodominant peptide in a given response. In addition, Ag-specific TCD8+ populations 
are examined using MHC I tetramer reagents, which fail to detect cells that have 
internalized their TCR due to activation.  
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Figure 1. Schematic representation of the “hole in the repertoire” posited to exist after 
SAg exposure. SAg-reactive cells are shown in dark grey, whereas T cell clones that do 
not bind SAg are represented in light grey. 
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1.8 Rationale and hypothesis 
Previous investigations suggest that SAg administration can cause the deletion or 
functional inactivation of cells in the T cell compartment (54, 264, 271). The human and 
mouse response to IAV is known to contain T cell populations for immunodominant 
antigens that bear SAg-reactive Vβ regions (262, 263). However, surprisingly little work 
has been done to investigate how SAgs affect antiviral T cell responses. Most work to date 
has focussed on CD4+ T cell responses to IAV in the context of active IAV infection, which 
can make it difficult to dissect out the mechanisms underlying any observed changes in the 
immune response (265, 266). In addition, the effect of SAgs on antigen-specific TCD8+ 
has not been comprehensively examined. Therefore, I hypothesize that bacterial SAgs will 
alter the magnitude and/or breadth of the CD8+ T cell responses to IAV. 
1.9 Specific aims 
i. Characterize how exposure to bacterial SAgs affects the magnitude and the breadth of 
primary, recall and memory TCD8+ responses to IAV in a mouse model.  
ii. Determine the mechanism behind the immunodominance changes observed in aim i, 
with specific attention to how this mechanism differs depending on the phase of the IAV-
specific immune response. 
iii. Evaluate the effect of bacterial SAgs on the functional capacity and fate of epitope-
specific TCD8+. 
iv. Determine the effect of bacterial SAgs on human virus-specific memory TCD8+, and 
whether the mechanisms behind these changes are the same as in the mouse model. 
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Chapter 2: Materials and Methods 
2.1 Ethics 
All animal experiments and husbandry was carried out according to the guidelines set out 
by the Canadian Council on Animal Care (CCAC) under protocols (AUP #2010-241 and 
AUP #2018-093) approved by the Animal Use Subcommittee at Western University. 
Human blood was collected from healthy donors that had provided written informed 
consent under a protocol (HSREB #5545) that had been approved by the Western 
University Research Ethics Board for Health Sciences Research Involving Human 
Subjects. Our inclusion criteria consisted of healthy volunteers between 18 and 100 years 
of age who were able to give free and informed consent. Donors were excluded if they fell 
outside of the age range, were pregnant or if they had a psychiatric illness. 
2.2 Mice 
Female BALB/c mice between 8 and 16 weeks of age were purchased from Charles River 
Canada (St. Constant, QC) and housed in the animal facility at the University of Western 
Ontario. These mice were housed and treated according to the guidelines set out by the 
Canadian Council on Animal Care.  
2.3 Cell culture 
Madin-Darby canine kidney (MDCK) cells were cultured in Dulbecco’s modified Eagle 
media (DMEM) plus 10% fetal calf serum (FCS). The J774 mouse macrophage cell line 
was kindly given by Dr. Bryan Heit (Western University) and maintained in DMEM plus 
10% FCS. The T2 human lymphoblast cell line was received from Dr. Tania Watts 
(University of Toronto) and cultured in complete Roswell Park memorial institute (cRPMI) 
media. This media consisted of 10% FCS, 2 mM Gluta-MAX-I, 0.1 mM MEM non-
essential amino acids, 1 mM sodium pyruvate, 10 mM HEPES buffer, 100 μg/mL 
streptomycin and 100 U/mL penicillin. All cultures were kept at 37ºC in a humidified tissue 
culture incubator plus 6% CO2. 
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2.4 Preparation and injection of SAg 
Recombinant SEB and SEA produced in Escherichia coli BL21 was purified by the 
McCormick lab at Western University as detailed elsewhere (1, 2). For all experiments 
involving SEB, BALB/c mice were given 50 μg of SEB in 200 μL of phosphate buffered 
saline (PBS) by intraperitoneal (i.p.) injection. A mutant version of SEB that has attenuated 
binding to the T cell receptor (SEBN23A) was also used in one experiment as a negative 
control for T cell receptor involvement. Mycoplasma arthritidis mitogen (MAM) was 
kindly provided by Dr. Hong-Hua Mu of the University of Utah. MAM was purified and 
prepared as detailed in previous publications (3, 4). Briefly, M. arthritidis was grown to 
senescent phase in autoclaved modified Edward-Hayflick medium, after which the whole 
culture was subjected to (NH4)2SO4 fractionation. This was followed by sequential rounds 
of gel filtration and cation-exchange chromatography prior to the final purification on a 
fast protein liquid chromatography (FPLC) column.  The in vivo dose for the mouse 
experiments was 50 ng per mouse in 200 μL PBS+0.2% bovine serum albumin (BSA), 
delivered by intraperitoneal (i.p.) injection. 
2.5 Preparation and administration of IAV 
Influenza A virus (IAV) was propagated by inoculation from a stock IAV solution into the 
allantoic cavity of 10-day-old embryonated chicken eggs. Allantoic fluid was harvested 
and pooled to create a new stock solution used for all subsequent experiments. Six different 
IAV strains were used, with A/Puerto Rico/8/1934 H1N1 (PR8) being used for most 
experiments. For other experiments, the strains A/Northern Territory/60/1968 H3N2 
(NT60) (5), A/Hong Kong/01/1968 H3N2 (HK) (5), J1 (a strain with hemagglutinin (HA) 
from HK and a PR8-derived core) (6), X31 (H3N2) (7) and sequential 12 (SEQ.12), a strain 
that was generated by serial passage of PR8 in the presence of neutralizing antibodies 
directed against HA (8). The SEQ.12 strain of IAV has internal epitopes that are identical 
to IAV (PR8) though the external epitopes have been altered by sequential passage in the 
presence of neutralizing antibodies. Mice received an i.p. injection of the infectious 
allantoic fluid to expose their immune system to IAV without inducing the morbidity and 
mortality associated with intranasal IAV infection. The allantoic fluid was diluted 1:1 with 
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sterile PBS before injection of 500 μL (~600 hemagglutinating units) into the peritoneal 
cavity.  Measurement of the primary TCD8+ response to IAV was carried out on day 7 after 
IAV injection, save for one experiment where SEB was given on day 7 and the TCD8+ cell 
response to IAV was measured on day 10.  
Measurement of the recall response to IAV was done in the context of a prime-boost i.p. 
vaccination regime. The mice were given a priming i.p. dose of IAV (PR8) on day 0, 
followed by a boosting dose of IAV (SEQ.12) on day 30 (9, 10). This strain must be used 
for the boosting dose (as opposed to PR8) to avoid a neutralizing antibody response in vivo. 
The magnitude and breadth of the TCD8+ response was measured on day 37 by intracellular 
cytokine staining (ICS) IFNγ. The memory response to IAV was measured at least eight 
weeks after i.p. IAV administration. 
For the intranasal infection model, mice were given an intranasal dose of IAV (PR8) 
corresponding to 0.3 50% mouse lethal dose (MLD50). The objective was to induce 
morbidity without inducing mortality so that the TCD8+ cell responses can be measured on 
day 10 after infection. To administer the intranasal dose, the mice were briefly anesthetized 
using 20% (v/v) isoflurane (Baxter International) in a bell jar. Once the mice were 
unconscious 25 μL total of the virus solution was delivered dropwise into the nares of the 
mice at 12.5 μL per nare. The mice were briefly returned to the bell jar between a series of 
drops to ensure that they remained deeply anesthetized; conscious mice are prone to 
coughing that would prevent the solution from getting to the lungs. After infection, the 
mice were monitored for morbidity (lethargy, piloerection, etc.) as well as weight loss. Any 
mouse that lost 15% or more of their body weight was euthanized via cervical dislocation.  
2.6 Preparation and administration of rVV 
For the experiments involving recombinant vaccinia viruses (rVV), TCD8+ responses were 
measured on day 7 after i.p. virus injection. The viruses used were two rVV strains 
encoding NP147 (rVV-NP147) and HA518 (rVV-HA518) (from Dr. Jonathan Yewdell and Dr. 
Jack Bennink, National Institutes of Health (NIH)) expressed as ER targeted minigenes to 
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increase expression. The injection consisted of 5 million plaque forming units (pfu) 
delivered i.p. in 200 uL PBS.  
2.7 Intracellular cytokine staining 
In all cases, splenocytes were collected from each mouse, as well as peritoneal exudate 
cells (PECS) collected by peritoneal lavage with 1x PBS. To ensure an adequate number 
of cells were available for staining, PECS from mice within each treatment group were 
pooled together in the same tube. Both types of sample were treated with ammonium-
chloride-potassium (ACK) lysis buffer to remove erythrocytes before enumeration using a 
hemacytometer. For the intranasal model, BAL and lung cells were also collected. After 
sacrifice, BAL was collected via lavage with 1 mL of 1x PBS, repeated 3 times in order to 
collect the maximum number of cells. The lungs were then perfused with 1x PBS to remove 
contaminating peripheral blood mononuclear cells (PBMCs) and then homogenized using 
a glass homogenizer. 
The cells to be used for staining were then transferred to 96-well plates and stimulated in 
vitro with 500 nM of IAV-derived H2-Kd restricted peptides dissolved in 10% 
dimethylsulphoxide (DMSO). These peptides were kindly provided by Dr. Jack Bennink 
and Dr. Jonathan Yewdell of the National Institutes of Health, and were determined to be 
>95% pure by high-performance liquid chromatography (HPLC). Each peptide solution 
was stored at -30ºC in DMSO before dilution for in vitro usage. As a positive control, 
400,000 J774 cells pulsed with IAV (PR8) were also included. After 2 hours of incubation 
at 37ºC in a 6% CO2 incubator, brefeldin A (BFA) (Sigma-Aldrich) was added to all wells 
at a concentration of 0.1 mg/mL to stop cytokine export. The plate was then returned to the 
incubator for 3 additional hours before pelleting the cells by centrifugation and adding Fc 
block (clone 2.4G2 from hybridoma supernatant) for 20 minutes at 4ºC. All cells were then 
surface stained for 30 minutes in ice with anti CD8-APC (clone 53-6.7, eBioscience) before 
fixation with 1% paraformaldehyde (Electron Microscopy Sciences).  The cells were then 
stained with anti-IFNγ-FITC (clone XMG1.2, eBioscience) while simultaneously being 
permeabilized with 0.1% saponin overnight. The next day, the cells were washed and 
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resuspended in FACS buffer (1x PBS + 0.5% BSA) before reading via flow cytometry on 
a BD FACS Canto II flow cytometer. 
2.8 Surface staining 
Detection of specific Vβ region expression on bulk CD8+ T cells was accomplished using 
the Mouse Vβ TCR Screening Panel produced by BD Pharmingen. A female, 8-week old 
BALB/c mouse was sacrificed to procure a spleen, which was then mechanically 
homogenized and treated with erythrocyte lysis buffer. The splenocytes were then split into 
two equal portions and suspended in cRPMI +10% fetal calf serum (FCS) at a 
concentration of 2 million cells/mL. This was followed by stimulation with 500 ng/mL 
SEB or PBS and incubation for 3 days in a 6% CO2 incubator at 37ºC. The cells from each 
condition were then stained with anti-mouse CD8α-Alexa Fluor 647 (clone 53-6.7, 
eBioscience) and one of the FITC-conjugated anti-Vβ antibodies in the screening panel 
before analysis via flow cytometry. 
To detect the type of Vβ region possessed by IAV epitope-specific TCD8+ from mice 
treated with SEB or PBS before i.p. IAV vaccination, the aforementioned surface and 
intracellular staining protocols were used with a few modifications. Detection of 
intracellular IFNγ was accomplished using an antibody conjugated to PerCP-Cy5.5 (clone 
XMG1.2, eBioscience) rather than FITC. Staining of mouse Vβ regions was accomplished 
using the Mouse Vβ TCR Screening Panel produced by BD Pharmingen. 
For experiments in which cells were stained to determine the expression of fate-related 
markers, the following antibodies were used: Anti-mouse CD3e-APC (clone 145-2C11, 
BD Pharmingen), Anti-mouse Killer Cell Lectin Like Receptor G1 (KLRG1)-PerCP-
eFluor® 710 (clone 2F1, eBioscience), Anti-mouse/rat Bcl-2 PE-Cyanine7 (clone 10C4, 
eBioscience), Anti-mouse CD279 (Programmed Death-1 (PD-1)) APC-eFluor® 780 
(clone J43, eBioscience), Anti-mouse CD8α-Alexa Fluor 700 (clone 53-6.7, eBioscience), 
Anti-mouse CD127-PE (clone A7R34, eBioscience) and anti-mouse IFNγ-FITC (clone 
XMG1.2, eBioscience), Anti-mouse lymphocyte-activation gene 3 (LAG3)-PE-Cy7 (clone 
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C9B7W, eBioscience). Surface and intracellular (in the case of Bcl-2) staining was carried 
out as previously described in sections 2.7 and 2.8. 
2.9 Tetramer staining of mouse TCD8 
Two Alexa Fluor 488-conjugated tetramers were obtained from the NIH tetramer facility 
and used to detect epitope-specific CD8+ T cells. These were specific for T cells 
recognizing the H2-Kd restricted peptides TYQRTRALV and IYSTVASSL, corresponding 
to NP147 and HA518 respectively (11, 12). The tetramers were used for staining at a dilution 
of 1:200 in PBS+0.5% BSA. The cells were stained on ice with tetramer for 30 minutes 
before addition of an anti-CD8-APC (clone 53-6.7, eBioscience) (without washing off the 
tetramer) and incubation for another 30 minutes on ice. If the samples were not further 
stained with intracellular cytokines the cells were washed and read immediately on a flow 
cytometer (BD FACS Canto II). 
2.10 CD107a detection 
For detection of CD107a on the surface of epitope-specific TCD8+, splenocytes and PECs 
were harvested as described before and plated at 2 million cells per well before stimulation 
with 500 nM of IAV-derived peptide. At the same time, a 1:200 dilution of anti-mouse 
CD107a-Alexa Fluor 647 (clone 1D4B, Biolegend) plus 1 μM monensin (BD GolgiStop) 
was added to each well. The cells were then incubated for 5 hours in a 37ºC, 6% CO2 
incubator before further staining as applicable. 
2.11 In vivo killing assay 
Six naive female BALB/c mice were sacrificed via cervical dislocation and then had their 
spleens removed and homogenized to form a single cell suspension as previously 
described. Red blood cells were removed via ACK lysis and total viable lymphocytes were 
enumerated using Trypan blue staining and a hemacytometer. The cells were then pulsed 
with 500 nM of the indicated IAV-derived peptide or an irrelevant peptide for 45 minutes. 
The cell suspensions were then resuspended in PBS and divided into two equal aliquots of 
5 mL volume. Carboxyfluorescein succinimidyl ester (CFSE) dye was added to each tube 
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at a concentration of 2.5 μM (high) or 0.5 μM and incubated for 20 minutes at 37ºC with 
occasional gentle mixing. Free CFSE was then neutralized by adding cold FCS to each tube 
before centrifugation and an additional counting step to enumerate remaining live cells. 
The high and low-pulsed splenocytes were then mixed in equal volumes and equal portions 
of each population were confirmed by analysis on a flow cytometer. Once equal mixing 
was confirmed the cells were resuspended in 200 μL PBS and 10 million cells were injected 
into the tail vein of the recipient BALB/c mice. After 1, 2 or 4 hours the mice were 
sacrificed and the splenocytes isolated as detailed earlier. For each condition, 2,000 CFSE+ 
events were collected. 
2.12 RT-PCR of lung and BAL samples for detection of IAV 
Lungs and BAL were harvested from the mice as previously described in section 2.7. In 
order to measure the greatest amount of virus, the lungs and BAL were extracted and 
processed on day 4 after IAV infection (13). After weighing, these samples were snap 
frozen on dry ice and stored in aliquots at -80ºC until extraction of RNA. Homogenization 
of the lung tissue was done using a rotor-stator homogenizer and enough diethyl 
pyrocarbonate (DEPC) treated PBS to create a 10% (w/v) solution. The RNA from the lung 
samples and BAL fluid was then isolated using a PureLink RNA Mini Kit (Ambion, Life 
Technologies). Equal volumes of RNA solution from each sample were then reverse-
transcribed using SuperScript VILO cDNA synthesis kit (ThermoFisher) before using for 
real-time reverse-transcription polymerase chain reaction (RT-PCR). The primers and 
probe used to detect IAV matrix (M1) protein were identical to those used by the Centres 
for Disease Control for universal detection of influenza A viruses (2009). GAPDH primer 
and probe sets were also used to confirm that the SEB treatment is not skewing the amount 
of cells in the sample. The RT-PCR reaction was run using TaqMan Fast Universal PCR 
Master Mix (Applied Biosystems) using an Applied Biosystems StepOne Plus RT-PCR 
system. 
2.13 Detection of infectious IAV by TCID50 assay 
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In order to compare the amount of infectious IAV between treatment groups, the samples 
of lung and BAL homogenate were used in a 50% tissue culture infectious dose (TCID50) 
assay. An aliquot of the 10% (w/v) solution of lung homogenate from mice on day 4 after 
intranasal IAV infection was clarified by low speed centrifugation, and 30 μL of this 
solution was set aside for the assay. Equal amounts of BAL fluid from each treatment group 
was also clarified by centrifugation and set aside to be used for this assay. MDCK cells 
were cultured in DMEM + 10% FCS before use in this assay. When adequate numbers of 
MDCK cells had been grown, 96-well U-bottom plates were prepared for the assay by 
adding 90 μL of DMEM + 0.0002% L-1-Tosylamide-2-phenylethyl chloromethyl ketone 
(TPCK) trypsin (Sigma-Aldrich) to each well. Before addition of the MDCK cells, 10 μL 
of lung or BAL sample was added to the first row of the plate in triplicate then serially 
diluted down the columns using a multichannel pipettor. The MDCK cells were washed to 
remove residual FCS, re-suspended in DMEM + 0.0002% TPCK trypsin and added to 
every well (at 25,000 cells/well). The plates were then put in the incubator and the virus in 
the samples was allowed to adsorb to the cells overnight. The next day, the supernatant was 
removed and replaced with 200 μL of fresh DMEM + 0.0002% TPCK trypsin. Four days 
later, 150 μL of supernatant was removed in each well and transferred to a new 96-well 
plate before addition of 50 μL 0.5% adult chicken red blood cells in Alsever’s solution 
(Charles River Avian Vaccine Services). The plates were then placed at 4ºC for 1 hour 
before observation of the hemagglutination pattern of the wells. TCID50 was then 
calculated using the method of Reed and Muench (14). 
2.14 IAV-specific Antibody titration 
After sacrificing the mice by cervical dislocation, cardiac puncture was carried out to 
retrieve blood samples. These samples were then centrifuged at 17,000×g for 40 minutes 
at 4ºC to isolate serum for use in antibody detection experiments. IAV-specific IgM and 
IgG2b were detected using Invitrogen eBioscience Ready-SET-Go! Kits (kindly provided 
by the DeKoter lab at Western University) after incubation on plates coated with IAV-
infected MDCK cell lysate generated according to the protocol detailed by Benton et. al. 
(15). Briefly, MDCK cells were infected with IAV (PR8) at a multiplicity of infection 
(MOI) of 1:1 before harvesting 36 hours later. The cell pellet was then resuspended in PBS 
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containing protease inhibitor and subjected to three freeze-thaw cycles to lyse the cells.  
Enzyme-linked immunosorbent assay (ELISA) plates were then coated with this lysate 
diluted 1:400 in ELISA coating buffer and blocked with PBS plus 2% FCS for 1 hour. The 
plates were then washed and mouse serum samples serially diluted in ELISA assay diluent 
were applied to the wells. The remainder of the assay was carried out according to 
instructions supplied by the manufacturer. 
2.15 Human PBMC preparation and culture  
Eight healthy donors ranging in age from 21 to 39, four males and four females, were 
recruited (Table 1). Selection of these donors was based on possession of the HLA-A2 
allele detected via surface staining of isolated PBMCs (ThermoFisher, clone BB7.2). 
PBMCs were isolated from heparinized whole blood by density gradient centrifugation 
using low-endotoxin Ficoll-Paque PLUS (GE Healthcare Life Sciences). An aliquot of 
PBMCs was set aside for immediate tetramer staining, and the remainder was seeded at 
2106 cells/mL Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% 
heat-inactivated fetal calf serum, 2 mM GlutaMAX-ITM, 0.1 mM MEM nonessential amino 
acids, 1 mM sodium pyruvate, 10 mM HEPES buffer, 100 U/mL penicillin and 100 µg/mL 
streptomycin in a 6-well tissue culture plate. Cultures were left untreated or stimulated with 
100 ng/mL SEB or with 20 ng/mL MAM. After 3 days, cells were washed thoroughly to 
remove residual SAgs. The washing step was repeated on day 4, and cultures were either 
halted or continued until day 7 or day 11 as indicated.    
                      Table 1. 
Donor ID Sex Age 
Seasonal flu vaccination 
within 3 months prior to 
blood draw 
1 M 39 Yes 
2 F 28 No 
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3 M 31 No 
4 F 25 No 
5 F 21 No 
6 M 33 Yes 
7 M 27 No 
8 F 24 No 
 
2.16 Dextramer and Tetramer staining of human PBMCs 
The dextramer staining procedure is based off of the protocols supplied by Immudex. 
Human PBMCs were enumerated and 1 million cells were put into each 12 x 75 mm 
polystyrene tube for staining either individually or singly with dextramers bearing HLA-
A*0201+ MHCI molecules loaded with one of the following peptides: GLCTLVAML 
(Epstein-Barr virus, BMLF-1280-288), GILGFVFTL (Influenza A virus M158-66), 
NLVPMVATV (human Cytomegalovirus (CMV), pp65495-503) and ALIAPHAV (nonsense 
peptide) as a negative control. Each sample was then surface stained with α-human CD8α-
FITC clone SK1 from eBioscience. Staining with both the CD8α antibody and the 
dextramers was carried out according the instructions of their respective suppliers. For 
most experiments, HLA-A*0201+ MHCI tetramers prepared by the NIH tetramer facility 
specific for the same IAV and cytomegalovirus (CMV) epitopes (GILGFVFTL and 
NLVPMVATV) were used to stain the cells on day 0, 3,7 and 11. Staining was carried out 
at 4ºC for 30 minutes before adding CD8α-FITC (BD Biosciences, clone SK1, isotype 
mouse IgG1κ) for an additional 30 minute incubation. Five minutes prior to analysis via 
flow cytometry, 5 μL of eBioscience 7-AAD Viability Staining Solution was added per 
million cells in the sample. 
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Gating analysis was done by first excluding dead cells, which stain positive for 7-AAD. 
After gating on the putative lymphocyte population as determined by FSC-A and SSC-A 
characteristics, doublets were then excluded based on FSC-W versus FSC-H and SSC-W 
versus SSC-H measurements. CD8α+ cells were then gated on and examined for tetramer 
or dextramer binding. 
2.17 51Cr release assay 
Human HLA-A2+ T2 cells (kindly provided by Dr. Tania Watts, University of Toronto) 
were pulsed overnight with 2 μM of the M158-66 peptide or vehicle for use as target cells in 
the assay. The next day, these cells were washed and resuspended in 100 μL of PBS, then 
labelled with 100 μCi of 51Cr in saline (Perkin-Elmer) for 1.5 hours. PBMCs that had been 
cultured for 11 days with SEB (100 ng/mL) were then harvested and stained with human 
Alexa Fluor 647-conjugated tetramer recognizing the M158-66  peptide in the context of 
HLA-A2 as previously described. After staining, tetramer-positive cells were then isolated 
by incubating with Miltenyi anti-Cy5/anti Alexa Fluor 647 MicroBeads prior to positive 
selection with a Miltenyi MS column according to the manufacturer’s protocol. Column-
binding fractions were then incubated with the aforementioned T2 target cells in a 96-well 
U-bottom plate at various effector:target ratios for 8 hours, after which the plate was 
centrifuged and the supernatants collected. The amount of radioactive Cr in the supernatant 
was then assessed using a Wallac Wizard 1470 automatic gamma counter.  
2.18 Flow cytometry and analysis 
All FACs data was collected using a FACs Canto II flow cytometer from BD Biosciences 
and FACs Diva software. All gating and data analysis was done using Flowjo software, 
version 7.6 or 10 (TreeStar). 
2.19 Statistical Analyses 
Statistical significance was determined where appropriate by application of a two-way 
analysis of variance (ANOVA), paired or unpaired Student’s T-test using GraphPad Prism 
5 software. Values of p<0.05 were considered statistically significant. 
70 
 
2.20 References 
1. Chau, T.A., et al., Toll-like receptor 2 ligands on the staphylococcal cell wall 
downregulate superantigen-induced T cell activation and prevent toxic shock 
syndrome. Nat Med, 2009. 15(6): p. 641-8. 
 
2. Xu, S.X., et al., Superantigens subvert the neutrophil response to promote abscess 
formation and enhance Staphylococcus aureus survival in vivo. Infect Immun, 
2014. 82(9): p. 3588-98. 
 
3. Atkin, C.L., S. Wei, and B.C. Cole, The Mycoplasma arthritidis superantigen 
MAM: purification and identification of an active peptide. Infect Immun, 1994. 
62(12): p. 5367-75. 
 
4. Mu, H.H., et al., Engagement of Toll-like receptors by mycoplasmal superantigen: 
downregulation of TLR2 by MAM/TLR4 interaction. Cell Microbiol, 2005. 7(6): 
p. 789-97. 
 
5. Bennink, J.R., et al., Recognition of cloned influenza virus hemagglutinin gene 
products by cytotoxic T lymphocytes. J Virol, 1986. 57(3): p. 786-91. 
 
6. Bedoya, F., et al., Viral antigen induces differentiation of Foxp3+ natural 
regulatory T cells in influenza virus-infected mice. J Immunol, 2013. 190(12): p. 
6115-25. 
 
7. Bouvier, N.M. and A.C. Lowen, Animal Models for Influenza Virus Pathogenesis 
and Transmission. Viruses, 2010. 2(8): p. 1530-1563. 
 
8. Das, S.R., et al., Defining influenza A virus hemagglutinin antigenic drift by 
sequential monoclonal antibody selection. Cell Host Microbe, 2013. 13(3): p. 
314-23. 
 
9.  (12594287) Woodberry, T., et al., Prime boost vaccination strategies: CD8 T cell 
numbers, protection, and Th1 bias. J Immunol, 2003. 170(5): p. 2599-604 
 
10. Sabarth, N., et al., Comparison of single, homologous prime-boost and 
heterologous prime-boost immunization strategies against H5N1 influenza virus 
in a mouse challenge model. Vaccine, 2010. 28(3): p. 650-6. 
 
11. Rotzschke, O., et al., Isolation and analysis of naturally processed viral peptides 
as recognized by cytotoxic T cells. Nature, 1990. 348(6298): p. 252-4. 
 
12. Tamura, M., et al., Definition of amino acid residues on the epitope responsible 
for recognition by influenza A virus H1-specific, H2-specific, and H1- and H2-
71 
 
cross-reactive murine cytotoxic T-lymphocyte clones. J Virol, 1998. 72(11): p. 
9404-6. 
 
13. Meunier, I., et al., Infection with a Mouse-Adapted Strain of the 2009 Pandemic 
Virus Causes a Highly Severe Disease Associated with an Impaired T Cell 
Response. PLoS One, 2015. 10(9): p. e0138055. 
 
14. Reed, L.J. and H. Muench, A SIMPLE METHOD OF ESTIMATING FIFTY 
PER CENT ENDPOINTS12. American Journal of Epidemiology, 1938. 27(3): p. 
493-497. 
 
15. Benton, K.A., et al., Heterosubtypic immunity to influenza A virus in mice 
lacking IgA, all Ig, NKT cells, or gamma delta T cells. J Immunol, 2001. 166(12): 
p. 7437-45. 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
Chapter 3: Results 
3.1 In vitro stimulation of BALB/c splenocytes with SEB 
decreases the detectability of TCD8+ bearing certain Vβ 
regions. 
It has been previously reported that SEB stimulation results in the anergy and/or deletion 
of T cells (1, 2, 3). To determine if this can be observed in the context of a single stimulation 
of SEB in vitro, a BALB/c mouse was sacrificed and the splenocytes were stimulated in a 
tissue culture plate with 500 ng/mL of purified SEB. Three days later, at the peak of SEB-
induced proliferation (4), the splenocytes were divided into separate aliquots and stained 
for expression of CD8 and one of 15 different mouse Vβ regions prior to interrogation via 
flow cytometry. CD8+ T cells bearing Vβ regions that bind SEB (Vβ7, 8.1/8.2 and 8.3 as 
denoted by the dashed boxes in Figure 2) decreased in percentage abundance after SEB 
stimulation as compared with splenocytes cultured with PBS alone. Though Vβ3 and 
Vβ17a also bind SEB they are not found in BALB/c mice due to genetic deletion by 
endogenous retroviruses (5). It needs to be noted that this experimental setup cannot 
distinguish between a loss of staining as a result of cell death and due to TCR 
internalization following T cell activation. 
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Figure 2. In vitro culture of BALB/c splenocytes with SEB results in reduced 
detectability of TCD8+ bearing SEB-binding Vβ regions. These data derive from 
analysis of a 3-day splenocyte culture in the presence of PBS or 500 ng/mL SEB. The cells 
were harvested 3 days after SEB addition and the Vβ usage by bulk TCD8+ was determined 
using a BD Vβ screening kit.  
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3.2 SEB alters the IAV-specific immunodominance hierarchy 
in a mouse model of IAV vaccination 
In BALB/c mice, the TCD8+ immunodominance (ID) hierarchy has been well 
characterized (6). Most of the TCD8+ that participate in the primary response to IAV are 
specific for the NP147 peptide, with the remainder of the response directed against PB2289, 
HA518, NP39, HA462 and NP218 in descending order of total cell number. It has also been 
established that the primary TCD8+ response to IAV administered as an i.p. injection is 
greatest in magnitude (total number of IAV-specific TCD8+) after one week (7). The i.p. 
route was chosen in order to initiate a measurable TCD8+ response to IAV without inducing 
morbidity, which could otherwise make the interpretation of our results difficult. To 
determine the effect of SEB on the IAV-specific response, 50 μg of purified SEB was 
delivered as an i.p. injection 3 days before vaccination with IAV. This amount of SEB does 
not induce measurable morbidity or mortality in BALB/c mice, as this strain lacks the 
humanized MHC II region necessary for efficient SEB binding (8). The i.p. route also does 
not result in active viral propagation, as cells in the peritoneal compartment lack sialic acid 
receptors. Other studies have also established that the peak TCD8+ proliferation induced 
by SEB occurs on day 3 after injection (4). To detect Ag-specific TCD8+, ICS for IFNγ 
expression was utilized. This method relies on the fact that epitope-specific TCD8+ produce 
IFNγ when briefly re-stimulated with their cognate peptide (9). ICS for IFNγ reliably 
detects epitope-specific TCD8+ capable of making effector cytokines (10).  
On day 10 post-SEB injection (day 7 after IAV injection) the mice were sacrificed and the 
PECs were collected by sequential lavage. To ensure collection of adequate numbers of 
cells for staining, these samples were pooled within each treatment group. The spleen was 
then dissected and homogenized before both samples were assessed for IFNγ production 
in response to purified peptide via ICS. The splenic TCD8+ response of mice injected with 
PBS before IAV vaccination demonstrates the expected ID trend in terms of percentage 
(Fig. 3A) and absolute number of epitope-specific TCD8+ (Fig. 3B). However, SEB-
injected animals had significantly higher numbers of splenic TCD8+ specific for NP147, 
HA518 and HA462 by percentage of TCD8
+ as well as by absolute number (with the addition 
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of a less striking increase in NP39-specific cells) (Fig. 3A,B). In the case of HA518-specific 
TCD8+ this augmentation was sufficient to render this population subdominant only to the 
NP147 response, thus altering the typical ID hierarchy to IAV. Interestingly, the 
augmentation of select TCD8+ epitope-specific populations in the peritoneal cavity was 
only observed in terms of absolute number of epitope-specific TCD8+ in the SEB-treated 
animals, with an opposite trend being observed in terms of percentage (Fig. 3D,C). 
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Figure 3. Effect of SEB on the primary TCD8+ response to IAV in BALB/c mice. (A) 
Percentage of epitope-specific cells among all TCD8+ in the spleen, as detected using 
intracellular cytokine staining for IFNγ expression after stimulation with cognate peptide. 
(B) Absolute number of epitope-specific TCD8+ in the spleen, calculated based on total 
cell counts after splenic homogenization. The equivalent (C) percentage data and (D) 
absolute cell number are shown for PECs collected from mice and pooled within each 
experiment. N=26 per group representing 5 independent experiments for the splenic data, 
while the PEC data has a corresponding N=5. Bars represent mean +SEM (*, p<0.05, **, 
p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
 
 
NP147 PB2289 HA518 NP39 HA462 NP218
0
1
2
3
4
PBS
SEB
P
e
rc
e
n
t 
IF
N

+
 o
f 
C
D
8
+
 s
p
le
n
o
c
y
te
s
NP147 PB2289 HA518 NP39 HA462 NP218
0
100000
200000
300000
400000
PBS
SEB
A
b
s
o
lu
te
 n
u
m
b
e
r 
o
f
 I
F
N

+
 c
e
ll
s
 p
e
r 
s
p
le
e
n
NP147 PB2289 HA518 NP39 HA462 NP218
0
5
10
15
PBS
SEB
P
e
rc
e
n
t 
IF
N

+
 o
f 
C
D
8
+
 P
E
C
S
NP147 PB2289 HA518 NP39 HA462 NP218
0
20000
40000
60000
80000
PBS
SEB
A
b
s
o
lu
te
 n
u
m
b
e
r 
o
f 
IF
N

+
P
E
C
S
 p
e
r 
m
o
u
s
e
***
***
**
***
***
* ***
*
**
***
*
**
*
A 
NP147 PB2289 HA518 NP39 HA462 NP218
0
1
2
3
4
PBS
SEB
P
e
rc
e
n
t 
IF
N

+
 o
f 
C
D
8
+
 s
p
le
n
o
c
y
te
s
NP147 PB2289 HA518 NP39 HA462 NP218
0
100000
200000
300000
400000
PBS
SEB
A
b
s
o
lu
te
 n
u
m
b
e
r 
o
f
 I
F
N

+
 c
e
ll
s
 p
e
r 
s
p
le
e
n
NP147 PB2289 HA518 NP39 HA462 NP218
0
5
10
15
PBS
SEB
P
e
rc
e
n
t 
IF
N

+
 o
f 
C
D
8
+
 P
E
C
S
NP147 PB2289 HA518 NP39 HA462 NP218
0
20000
40000
60000
80000
PBS
SEB
A
b
s
o
lu
te
 n
u
m
b
e
r 
o
f 
IF
N

+
P
E
C
S
 p
e
r 
m
o
u
s
e
***
***
**
***
***
* ***
*
**
***
*
**
*
B 
77 
 
 
 
 
 
 
 
 
 
 
 
 
NP147 PB2289 HA518 NP39 HA462 NP218
0
1
2
3
4
PBS
SEB
P
e
rc
e
n
t 
IF
N
 +
 o
f 
C
D
8
+
 s
p
le
n
o
c
y
te
s
NP147 PB2289 HA518 NP39 HA462 NP218
0
100000
200000
300000
400000
PBS
SEB
A
b
s
o
lu
te
 n
u
m
b
e
r 
o
f
 I
F
N
 +
 c
e
ll
s
 p
e
r 
s
p
le
e
n
NP147 PB2289 HA518 NP39 HA462 NP218
0
5
10
15
PBS
SEB
P
e
rc
e
n
t 
IF
N
 +
 o
f 
C
D
8
+
 P
E
C
S
NP147 PB2289 HA518 NP39 HA462 NP218
0
20000
40000
60000
80000
PBS
SEB
A
b
s
o
lu
te
 n
u
m
b
e
r 
o
f 
IF
N
 +
P
E
C
S
 p
e
r 
m
o
u
s
e
***
***
**
***
***
* ***
*
**
***
*
**
*
C 
NP147 PB2289 HA518 NP39 HA462 NP218
0
1
2
3
4
PBS
SEB
P
e
rc
e
n
t 
IF
N
 +
 o
f 
C
D
8
+
 s
p
le
n
o
c
y
te
s
NP147 PB2289 HA518 NP39 HA462 NP218
0
100000
200000
300000
400000
PBS
SEB
A
b
s
o
lu
te
 n
u
m
b
e
r 
o
f
 I
F
N
 +
 c
e
ll
s
 p
e
r 
s
p
le
e
n
NP147 PB2289 HA518 NP39 HA462 NP218
0
5
10
15
PBS
SEB
P
e
rc
e
n
t 
IF
N
 +
 o
f 
C
D
8
+
 P
E
C
S
NP147 PB2289 HA518 NP39 HA462 NP218
0
20000
40000
60000
80000
PBS
SEB
A
b
s
o
lu
te
 n
u
m
b
e
r 
o
f 
IF
N
 +
P
E
C
S
 p
e
r 
m
o
u
s
e
***
***
**
***
***
* ***
*
**
***
*
**
*
D 
78 
 
Flow cytometric evaluation of IFNγ-expressing cells can also help reveal how much 
relative IFNγ is present on a per cell basis. IFNγ+ CD8+ cells from both PBS and SEB 
conditions were gated on using Flowjo software and the geometric mean fluorescence 
intensity (gMFI) of each population was calculated. The three most immunodominant 
TCD8+ populations revealed no difference between SEB and PBS-injected animals in 
terms of IFNγ production on a per cell basis (Fig. 4). This indicates that while SEB 
augments the percentage and absolute number of splenic epitope-specific TCD8+, it does 
not enhance or diminish the ability of a given cell to produce IFNγ. 
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Figure 4. gMFI of IFNγ-FITC for three selected splenic epitope-specific populations. 
The gMFI values were based off of CD8+ events that also express IFNγ in response to 
peptide stimulation. The actual fluorescence value represents the average brightness of the 
IFNγ-FITC staining per cell. N=23 per group representing 5 independent experiments. Bars 
represent mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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As a control to roughly assess whether SEB impacts the ability of the mouse immune 
system to respond to whole IAV rather than purified peptide, J774 macrophages were 
infected with IAV before using the infected cells to stimulate TCD8+ in an ICS. The J774 
cell line was chosen because it shares an MHC haplotype with BALB/c mice and is capable 
of being infected with IAV (11). This experiment demonstrated that SEB augments the 
percentage and absolute number of total TCD8+ that respond to IAV-infected J774 cells 
(Fig. 5). 
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Figure 5. Percentage (A) and absolute number (B) of TCD8+ in the spleen producing 
IFNγ in response to stimulation with IAV-infected J774 cells. J774 cells were infected 
with IAV for 5 hours before washing and incubating with splenocytes and PECs. N=7 
(PBS) or 6 (SEB) per group, representing 2 independent experiments. Bars represent mean 
+SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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Another parameter of the TCD8+ response to IAV that can be gleaned from the ICS 
experiments is the effect of SEB on the total percentage and absolute number of all TCD8+, 
not just IAV-specific cells. This is an additional, though indirect, control to confirm that 
the SEB used is biologically active and capable of causing TCD8+ expansion. Gating on 
live bulk TCD8+ demonstrated that, as is the case for total IAV-specific TCD8+, the 
percentage and number of bulk TCD8+ in SEB-treated animals is significantly increased 
compared to the TCD8+ response in animals injected with PBS (Fig. 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
Figure 6. Effect of SEB on the primary TCD8+ response to IAV in BALB/c mice. (A) 
Percentage of overall TCD8+ in the spleen out of single live cells. (B) Absolute number of 
total TCD8+ in the spleen, calculated based on total cell counts after splenic 
homogenization. N=26 per group representing 5 independent experiments. Bars represent 
mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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Though the ICS for IFNγ is a sensitive and specific assay for identifying epitope-specific 
TCD8+, it is limited by the fact that only cells capable of producing IFNγ can be detected. 
IAV-specific TCD8+ are all typically capable of producing IFNγ after exposure to cognate 
peptide (12), but given the evidence for SEB-induced anergy (13, 14, 15) it is necessary to 
validate the observed differences between PBS- and SEB-injected animals using MHC I 
tetramers. Tetramer reagents are composed of four MHC molecules, each loaded with the 
peptide of interest, which have been joined together into a single complex (16). This 
complex is then conjugated to a fluorophore that is detectable via flow cytometry. This 
reagent is capable of binding to the TCR of cells that are specific for the peptide that has 
been loaded onto the tetramer. NP147- and HA518-loaded tetramers were synthesized by and 
obtained from the NIH Tetramer Facility; these tetramers were chosen because they 
identified the epitope-specific populations that had been significantly enhanced in number 
as determined by ICS. Mice that had been injected with PBS/SEB followed by vaccination 
with IAV were sacrificed to obtain splenocytes that were then stained with NP147- and 
HA518-loaded tetramers, followed by surface staining for CD3 and CD8 expression. There 
was a trend towards an increased percentage of tetramer+ cells among the CD3+ CD8+ 
compartment in the spleen for both NP147- and HA518-specific population (Fig. 7A), which 
became significant when absolute splenic cell numbers were factored in (Fig. 7B). The 
absolute numbers of epitope-specific cells identified via ICS versus tetramer staining were 
similar, demonstrating that ICS is a reliable method for detection of epitope-specific 
TCD8+ in the context of experiments with SEB. 
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Figure 7. Effect of SEB on the (A) percentage and (B) number of CD3+ CD8+ epitope-
specific splenocytes as determined by tetramer staining. Mice were injected with SEB 
or PBS three days before injection of IAV. Seven days after IAV injection PECs and 
splenocytes were harvested for tetramer staining. N=8 per group pooled from 2 
independent experiments. Bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***, 
p<0.001, unpaired Student’s t-test). 
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3.3 Augmentation of the response to IAV by SEB lasts several 
days after the peak TCD8+ response to IAV 
Given that SEB has previously been thought to induce T cell anergy, it is possible that the 
augmented IAV-specific TCD8+ response on day 7 was transient and that later time points 
would reveal a loss of IAV-specific cells in the spleens of SEB-treated animals. To examine 
this possibility, BALB/c mice were injected as before with SEB or PBS three days before 
an i.p. vaccination with IAV, though this time the enumeration of TCD8+ specific for 
different IAV epitopes was carried out on days 3, 5, 9 and 11 in addition to day 7. This 
necessarily involved setting up different cohorts of mice that were sacrificed to obtain 
splenocytes at each of the aforementioned time points. As before, an ICS for IFNγ 
expression was carried out to examine the percentage and absolute number of cells specific 
for each IAV-derived epitope. Though the variability was high due to the low number of 
mice per time point, the data still shows a trend towards increased epitope-specific TCD8 
by percentage (Fig. 8A) and absolute number (Fig. 8B) in the SEB-treated animals versus 
those injected with PBS. For NP147 and HA518, this trend even reached statistical 
significance on days 9 and 11 in terms of percentage. These time points fall far past the 
time when other sources in the literature report the induction of T cell anergy/deletion by 
SEB (2, 17). 
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Figure 8. Primary response to IAV over the course of 11 days in PBS- versus SEB-
injected animals. All mice were injected with SEB 3 days before IAV vaccination on day 
0. Each time point represents data from a different cohort of 3 mice sacrificed on indicated 
days. The data from each individual mouse is plotted individually to show the degree of 
variation between animals. Data are expressed as (A) percentage of CD8+ cells that are 
IFNγ+ after stimulation with a given peptide as well as (B) the absolute number of splenic 
epitope-specific TCD8. N=3 per group. Bars represent mean ±SEM (*, p<0.05, **, p<0.01 
and ***, p<0.001, unpaired Student’s t-test). 
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3.4 TCD8+ expanded by SEB are functional in terms of 
degranulation and cytotoxic ability 
Though the ability to detect SEB-expanded IAV-specific TCD8+ by virtue of their ability 
to produce IFNγ suggests that these cells are functional effectors, it is possible that SEB 
renders these cells unable to carry out other functions such as degranulation and killing of 
IAV-infected cells. Expansion of a population does not always result in enhanced function 
(18), and given the established negative effect of SEB on the ability of CD4+ T cells to help 
B cells produce antibodies (19) the effect of SEB on TCD8+ function needed to be 
elucidated. TCD8+ are capable of killing cells through the perforin-granzyme pathway, 
which involves the release of cytotoxic granules from an activated TCD8+ (20). Granule 
exocytosis in response to stimulation with a cognate peptide results in the expression of 
CD107a on the surface of the T cell (21). To assess the effect of SEB on the ability of IAV-
specific TCD8+ to degranulate, splenocytes from mice that had been treated as before with 
PBS/SEB and IAV were pulsed with peptide in a modified ICS. At the start of the 
incubation with peptide, an anti-CD107a fluorescent Ab was added, enabling labelling to 
occur as soon as CD107a appeared on the cell surface. In addition, monensin was added to 
prevent surface CD107a from recycling back into the cell. As shown in Figures 9A and B, 
splenic TCD8+ from SEB-treated animals had a higher percentage and absolute number of 
CD107a-expressing cells than mice treated with PBS for all but one of the epitope-specific 
populations examined. This means that SEB is not inhibiting TCD8+ degranulation; rather, 
there is a significant increase in the SEB-inoculated animals as compared to PBS-treated 
mice for both parameters. Interestingly, the data suggest the opposite may be true when 
considering the amount of degranulation that takes place on a per cell basis. The gMFI of 
CD107a, or the amount of CD107a expressed per cell, was significantly decreased in the 
SEB animals when considering the NP147- and NP39-specific TCD8
+ populations. 
However, the absolute decrease in gMFI is minute, which may indicate that this difference 
is not biologically meaningful. 
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Figure 9. SEB increases the percentage and absolute number of IAV-specific TCD8+ 
expressing CD107a. Splenocytes were stimulated with IAV-derived peptide for 5 hours 
in the presence of anti-CD107a antibody before surface staining for CD3 and CD8, 
followed by intracellular staining for IFNγ. (A) Percentage and (B) absolute number of 
CD3+ CD8+ splenocytes that co-express IFNγ and CD107a. (C) CD107a-based gMFI was 
also calculated for quadruple+ cells. N=3 per group. Bars represent mean ±SEM (*, p<0.05, 
**, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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In terms of the primary TCD8+ response to IAV, perhaps the most biologically relevant 
readout for function is the ability of IAV-specific cells to kill their target cells in vivo. This 
can be accomplished in a mouse model using a CFSE-based in vivo killing assay that 
measures epitope-specific killing by TCD8+ based on the disappearance of peptide-pulsed 
cells that had been labelled with CFSE and injected into mice (22, 23). To measure the 
effect of SEB on the killing of NP147- and HA518-pulsed target cells by splenic TCD8
+ in 
vivo, BALB/c mice were injected with SEB or PBS three days before vaccination with 
IAV, as had been done in ICS and tetramer experiments (Fig. 3, Fig. 7). On day 7 after 
IAV injection, the mice were injected via the tail vein with cells that had been pulsed with 
an irrelevant peptide, NP147, or HA518 and labelled with various concentrations of CFSE 
before the cells were washed and mixed in equal numbers. After 4 hours, the mice were 
sacrificed and the splenocytes harvested for interrogation via flow cytometry. Increased 
killing results in a smaller CFSE peak in terms of cell number, and this difference is 
quantified and normalized based on the size of the peak corresponding to the cells pulsed 
with irrelevant peptide as well as naive mouse controls. Even though by 4 hours, the killing 
of NP147-pulsed cells in both PBS- and SEB-treated mice appeared to have reached 
saturation, there was significantly increased killing directed against the HA518-pulsed cells 
in the SEB-injected animals versus the PBS-injected mice (Fig. 10A). This was visible 
even without calculation based on the size of the peaks as they appeared on the flow 
cytometer (Fig. 10B). These results demonstrate that SEB administration augments the 
TCD8+ cytotoxic response to IAV vaccination in vivo. 
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Figure 10. Lytic ability of splenic epitope-specific TCD8+ after 4 hours of incubation 
in vivo. Splenocytes from naive donor BALB/c mice were pulsed with indicated peptides 
prior to labelling with CFSE. The cells were then washed and mixed in equal numbers 
before injection into mice that had been treated with PBS or SEB prior to IAV inoculation. 
Four hours later, the animals were sacrificed and the amount of killing determined by 
comparison of CFSE peak size to naive control mice. Killing was calculated using the 
following formula: {1-[(% IAV peptide-pulsed cells in primed mouse / % irrelevant 
peptide-pulsed cells in primed mouse) / (% IAV peptide-pulsed cells in naive mouse / % 
irrelevant peptide-pulsed cells in naive mouse)]} × 100. The killing shown in (A) was 
determined after a 4-hour incubation after injection. Typical CFSE peaks are shown in (B). 
N=4 per group, data pooled from 2 independent experiments. Bars represent mean +SEM 
(*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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3.5 SEB increases the magnitude of the IAV-specific TCD8+ 
response regardless of the IAV strain used for vaccination 
All experiments thus far involved the use of PR8 as the vaccination strain. This lab-adapted 
IAV strain is common for laboratory use as it is highly adapted for use in mice and for 
propagation in eggs (24). It is also only mildly pathogenic in the case of accidental human 
infection (25). This high degree of adaptation raises the question of whether or not SEB 
would have the same effect on a TCD8+ response induced by other IAV strains, including 
those more relevant for human illness. Therefore, the ICS experiment examining the effect 
of SEB on the primary response to vaccination with IAV (PR8) was repeated with four 
different IAV strains (Fig. 11A). Though the strains I utilized share a PR8-derived core 
they differ in their expression of surface membrane molecules such as HA and NA. Both 
J1 and X31 are artificial strains; J1 is an H3N1 PR8 reassortant (26) while X31 (27) is an 
H3N2 strain. NT60 and HK are both derived from naturally circulating viruses, with both 
representing seasonal H3N2 strains (28). Despite the differences between these viruses, 
SEB produced the same effect with the four test strains in terms of significantly increasing 
the response to NP147 (Fig. 11B-E) 
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Figure 11. Primary splenic TCD8+ response to different strains of IAV after SEB 
treatment, as determined by ICS for IFNγ expression. BALB/c mice were injected with 
SEB or PBS three days before i.p. injection with either X31, J1, NT60 or HK. Seven days 
later IFNγ expression by splenocytes in response to incubation with IAV-derived peptides 
was measured via ICS. (A) Depicts the different HA and NA proteins of each of the 
indicated strains in the context of the common PR8 viral core. Both (B) and (C) represent 
the absolute number of epitope-specific TCD8+ produced in response to vaccination with 
artificially-created lab strains of IAV, while (D) and (E) show the same response elicited 
by naturally circulating IAV strains. N values are indicated on each graph separately, while 
the bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s 
t-test). 
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3.6 SEB administration before infection with recombinant 
vaccinia virus reduces the number of VV-specific TCD8+  
The large changes in terms of the IAV-specific ID hierarchy induced by SEB 
administration raises the question of whether the same effect would be observed when 
IAV-derived peptides are presented in the context of a different virus. To answer this 
question, BALB/c mice in two separate experiments were given PBS or 50 μg SEB i.p. 
three days before infection with 5 million pfu of rVV encoding NP147 or HA518. Seven days 
after infection, at the peak of the TCD8+ response to rVV, the percentage and number of 
TCD8+ specific for epitopes derived from rVV and IAV were investigated via ICS for 
IFNγ. Interestingly, the epitope-specific TCD8+ recovered from the spleens of animals 
infected with rVV-NP147 were reduced in terms of percentage (Fig. 12A) and absolute 
number (Fig. 12B) for both the vaccinia epitopes and NP147. The same pattern was observed 
for the percentage (Fig. 12C) and absolute number (Fig. 12D) of splenic TCD8+ recovered 
from mice infected with rVV-HA518.  
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Figure 12. The TCD8+ response to vaccinia virus is reduced by administration of SEB. 
BALB/c mice were injected with PBS or 50 μg of SEB before i.p. infection three days post-
infection with 5 million pfu of a recombinant vaccinia virus expressing NP147 or HA518 
peptide as a cytosolic minigene. At the peak of the TCD8+ response, the mice were 
sacrificed and the percentage and number of TCD8+ specific for both IAV- and VV-derived 
epitopes were determined via ICS. (A) The percentage and (B) number of epitope-specific 
TCD8+ elicited in response to rVV encoding NP147 are shown for immunogenic VV 
peptides and for NP147. The equivalent data are shown for the (C) percentage and (D) 
absolute number of TCD8+ in elicited in response to rVV encoding HA518. N=4 per group. 
Bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s 
t-test). 
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3.7 Changes in the ID hierarchy are driven by Vβ expression 
among different TCD8+ populations 
One question that remained from the primary ICS experiments shown in Figure 3 was the 
explanation for why some epitope-specific TCD8+ populations (such as those recognizing 
NP147 and HA518) were expanded by SEB administration while others (such as those 
recognizing PB2289) were not. Since SEB is known to preferentially bind certain Vβ regions 
(29), it is possible that responsive populations predominantly express TCRs that use SEB-
reactive Vβ regions. To test this idea the primary ICS in BALB/c mice was repeated, this 
time examining the response to only one epitope per experiment. This enabled staining in 
parallel for 15 different mouse Vβ regions so as to determine the Vβ usage by IFNγ+ cells. 
For each animal the total proportion of cells that stained positive for a given Vβ out of the 
total population of epitope-specific cells with a detectable Vβ region was determined (Fig. 
13). The epitope-specific populations that were expanded by contact with SEB (NP147 and 
HA518) were dominated by the expression of SEB-reactive Vβ regions, while those that 
were not expanded (PB2289) showed no such skewing. This strongly suggests that the 
expansion of certain populations is due to their predominant usage of a Vβ region that can 
bind SEB. 
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Figure 13. Expression of different Vβ regions among splenic TCD8+ specific for three 
different epitopes. The Vβ makeup of each epitope-specific population was determined 
by co-staining for IFNγ and Vβ expression. The proportion of each epitope-specific 
population that expressed a given region was then calculated as a proportion of the whole 
for each individual mouse. Each bar represents data from a different animal, with the dark-
shaded segments denoting Vβ regions that are known to bind SEB.  
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If the changes observed during the primary response to IAV are dependent on the 
differential expression of Vβ regions among epitope-specific TCD8+, then use of a different 
SAg that binds the same Vβ regions as SEB should produce similar ID changes when 
administered before IAV. MAM is one such SAg. It also has the advantage of binding 
mouse MHC with higher affinity than many SAgs derived from S. aureus (30, 31). Of 
particular relevance is the fact that MAM binds Vβ8, which corresponds to the main family 
of Vβ found in the NP147- and HA518-specific TCD8
+ populations. As before, mice were 
injected i.p. with 50 μg of MAM three days before i.p. injection of IAV. ICS to enumerate 
epitope-specific TCD8+ revealed that mice having received MAM had an elevated 
percentage of NP147-specific cells (Fig. 14A). By absolute number both NP147- and HA518-
specific populations (as well as NP39) were significantly elevated in MAM-injected animals 
as compared to animals that received PBS, with no such increase observed for PB2289-
specific cells (Fig. 14B). This result recapitulates the pattern found in SEB-injected 
animals, suggesting that SAg Vβ specificity is driving the ID changes observed in the i.p. 
vaccination model. 
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Figure 14. Administration of MAM augments the primary TCD8+ response to IAV in 
a similar manner as SEB. Mice were injected i.p. with 50 μg MAM or PBS three days 
before injection of IAV. (A) Percentage of epitope-specific cells among all TCD8+ in the 
spleen, as detected using intracellular cytokine staining for IFNγ expression after 
stimulation with cognate peptide. (B) Absolute number of epitope-specific TCD8+ in the 
spleen, calculated based on total cell counts after splenic homogenization. N=8 for the PBS 
condition and N=7 for the MAM condition; data are pooled from 2 independent 
experiments. Bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, 
unpaired Student’s t-test). 
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If the augmentation of the NP147 and HA518 responses after contact with MAM and SEB 
were due to high expression of Vβ8, then the same ID changes should not be observed after 
administration of a SAg that targets different Vβ. One such SAg is SEA, which binds Vβ1, 
3, 10, 11 and 17 (32). Though both Vβ3 and Vβ17 are SEB-reactive, they are not expressed 
in BALB/c mice due to genetic deletion by endogenous retroviruses (33). Separate cohorts 
of mice were injected according to the primary vaccination protocol, replacing injection of 
50 μg SEB with 50 μg of SEA by the i.p. route, followed by i.p. injection of IAV. Analysis 
of epitope-specific populations by ICS showed that SEA produced no skewing of the ID 
hierarchy as judged by either the percentage of epitope-specific cells (Fig. 15A) or by their 
absolute numbers (Fig. 15B). This demonstrates that administration of a SAg that does not 
target the Vβ regions predominantly expressed by IAV-specific TCD8+ is unable to cause 
skewing of the ID hierarchy. 
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Figure 15. SEA administration does not change the IAV-specific TCD8+ ID hierarchy. 
Mice were injected i.p. with 50 μg of SEA three days before vaccination with an i.p. dose 
of IAV. (A) Effect of SEA on the percentage of IAV-specific TCD8+ and (B) absolute 
number of epitope-specific TCD8+. N=4 for each condition. Bars represent mean +SEM 
(*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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3.8 Changing the order of IAV and SEB administration results 
in increased TCD8+ responses towards all epitopes. 
Since bacterial superinfection is known to occur in patients hospitalized with IAV 
infection, additional experiments reversing the order of IAV/SAg exposure were 
performed. The objective was to examine what effect vaccinating with IAV before 
injection of SAg may have on the TCD8+ response to IAV. As before, these experiments 
were carried out in a BALB/c mouse model of primary i.p. IAV vaccination. IAV was 
injected i.p. four days before an i.p. dose of 50 μg SEB, after which three more days were 
allowed to elapse before the mice were sacrificed and an ICS carried out to enumerate the 
percentage and number of IAV-specific TCD8+. The design of this experiment was such 
that the peak of the TCD8+ response to IAV and proliferation induced by SEB fell on the 
same day. In this case the percentage (Fig. 16A) and absolute number (Fig. 16B) of splenic 
TCD8+ specific for almost all of the epitopes in the ID hierarchy were significantly 
increased, not just the epitope-specific populations that predominantly express TCRs with 
an SEB-reactive Vβ region. Despite the vigorous TCD8+ response, the mice displayed no 
morbidity aside from slightly ruffled fur. 
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Figure 16. Effect of SEB administration on the primary splenic TCD8+ response to 
IAV, where SEB is administered 3 days before the peak IAV-specific response. Mice 
were injected i.p. with IAV. On day 4 after IAV inoculation the mice were injected with 
SEB or PBS. An ICS for IFNγ expression was carried out on day 7 after IAV injection to 
examine the (A) percentage and (B) absolute number of splenic IAV-specific TCD8+ for 
each detectable epitope-specific population. N=8 per group, pooled from 2 independent 
experiments. Bars represent represent mean +SEM (*, p<0.05, **, p<0.01, ***, p<0.001 
and ****, p<0.0001, unpaired Student’s t-test). 
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Given the evidence from Figure 16 that SEB does not induce deletion or anergy of IAV-
specific TCD8+ when administered after IAV vaccination, it was relevant to ask whether 
SEB could be used to prolong the TCD8+ response to IAV. In this case IAV was 
administered to BALB/c mice as for Figure 16, except that SEB was injected on day 7 after 
IAV vaccination rather than on day 4. The effect of these interventions was then assayed 
via ICS three days later, which corresponds to day 10 post IAV injection. At this time point, 
the TCD8+ response to IAV should be diminishing. Though the magnitude of the IAV-
specific TCD8+ response was indeed slightly smaller than what is shown in Figure 16, there 
remained a statistically significantly increased response to some IAV epitopes as measured 
by the percentage (Fig. 17A) and for all epitopes by absolute numbers (Figure 17B) save 
for NP218. This shows that SEB injection after IAV exposure can be used to prolong a 
strong TCD8+ to IAV vaccination. 
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Figure 17. Effect of SEB administration on the primary splenic TCD8+ response to 
IAV, where SEB is administered during the peak IAV-specific response. Mice were 
injected with IAV i.p. 7 days before administration of SEB or PBS. Three days after this 
second injection an ICS for IFNγ expression was carried out to examine the effect of SEB 
on the (A) percentage and (B) absolute number of splenic IAV-specific TCD8+. N=8 per 
group, pooled from 2 independent experiments. Bars represent mean +SEM (*, p<0.05, **, 
p<0.01, ***, p<0.001 and ****, p<0.0001, unpaired Student’s t-test). 
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Though the increased magnitude of the response shown in Figure 17 is remarkable, it must 
be confirmed that these expanded TCD8+ are functional in terms of their cytotoxic 
capability. Fortuitously, the augmentation of the TCD8+ response by SEB was the greatest 
in magnitude for the dominant epitope NP147, which makes the NP147-specific TCD8
+ 
response the most suitable choice for assessment of the effect of SEB on cytotoxic function. 
BALB/c mice were injected with IAV i.p. before receiving either PBS or 50 μg SEB i.p. 
seven days later, followed by an in vivo killing assay examining NP147-pulsed cells after 
three days. As an additional condition the mice were sacrificed 1, 2 or 4 hours after 
injection of pulsed target cells to track the rate of killing in PBS- versus SEB treated 
animals. At all time points the killing of NP147-pulsed target cells was significantly greater 
in SEB-treated mice than in PBS-treated mice (Fig. 18). The time course also showed that 
this function was extremely rapid, with the killing of target cells in the SEB-injected 
animals being close to complete after just 4 hours of incubation. 
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Figure 18. The kinetics of NP147-specific CD8+ T cell-mediated cytotoxicity in PBS- 
and SEB-treated mice. Splenocytes from naive donor BALB/c mice were pulsed with the 
indicated peptide prior to labelling with CFSE. The cells were then washed and mixed in 
equal numbers before injection into mice that had been injected with PBS or SEB on the 
same day as the peak TCD8+ response to primary IAV administration. This assay was 
carried out 3 days after that injection, a total of 10 days after initial IAV administration. 
N=4 per group pooled from 2 independent experiments. Bars represent mean +SEM (*, 
p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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3.9 The effect of SEB in a prime-boost model of IAV 
vaccination depends on SEB administration time 
Having shown that SEB augments the magnitude of the primary TCD8+ response to IAV, 
it remained to be seen whether SEB was beneficial in the context of prime-boost 
vaccination strategies. These strategies involve administration of a vaccine in two separate 
doses to first create a primary immune response and then to create a boosted secondary 
response by re-vaccinating one month later. To assess whether SEB may be useful in this 
context, NP147- and HA518-tetramer-positive TCD8
+ were examined for their expression of 
KLRG1 and CD127 at the peak of the primary response to IAV. The timing of injections 
used for this experiment was the same as in Figure 3, as this experiment could be extended 
later to mimic the administration of SEB before a priming dose of IAV vaccine. KLRG1+ 
CD127- TCD8+ cells are characterized as terminal effectors, while KLRG1- CD127+ 
TCD8+ cells are considered memory precursors (34). Effective vaccination relies on the 
generation of memory precursors (35). Encouragingly, while the percentage (though not 
absolute number) of terminal effector TCD8+ specific for both NP147 and HA518 were 
reduced in SEB-injected animals, the percentage and absolute number of memory 
precursors were significantly increased in the same animals (Fig. 19). 
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Figure 19. SEB administration 3 days before IAV vaccination greatly increases the 
percentage and absolute number of KLRG1- CD127+ memory precursor cells that are 
specific for NP147 and HA518, as determined by tetramer staining. Mice were injected 
with SEB or PBS three days before i.p. injection of IAV. Splenocytes were then harvested 
on day 7 after IAV injection and stained with NP147- and HA518-specific tetramers before 
co-staining for KLRG1 and CD127 expression. N=4 per group. Bars represent mean +SEM 
(*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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Given that injection of SEB increases the number of memory precursors during the primary 
response to IAV vaccination, it stands to reason that the secondary response to IAV in mice 
injected with SEB before priming could also be increased. I used an experimental prime-
boost vaccination regimen for IAV-specific immunity in BALB/c mice. Accordingly,  I 
primed mice  with an i.p. injection of IAV (PR8) one month before a boosting dose of IAV 
(SEQ.12) was given (36, 37). Since IAV (SEQ.12) was created by serial passage of PR8 in 
the presence of several neutralizing antibodies (38), this virus escapes neutralization by the 
PR8-specific antibodies present in the mouse after priming and thus can induce a robust 
TCD8+ recall response. The magnitude of this recall response is typically measured one 
week after boosting with SEQ.12. BALB/c mice that were treated with SEB before priming 
had significantly increased percentage (Fig. 20A) and absolute number (Fig. 20B) of NP147- 
and HA518-specific TCD8
+. Therefore, the impact of SEB on the TCD8+ response can 
persist for more than a month after SEB exposure.  
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Figure 20. SEB administration before a priming dose of IAV (PR8) selectively 
increases the TCD8+ response to IAV as measured 7 days after a booster vaccination 
with IAV (SEQ.12). The mice were injected with PBS or SEB 3 days before IAV (PR8) 
injection. Thirty days after the initial IAV injection the mice were given a boosting dose 
of IAV (SEQ.12). One week after the booster injection the mice were sacrificed and the 
(A) percentage and (B) absolute number of splenic IAV-specific TCD8+ was measured by 
ICS for IFNγ. N=8 per group pooled from 2 independent experiments. Bars represent mean 
+SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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Though SEB exposure increases the magnitude of the TCD8+ recall response when given 
before a priming dose of IAV, this may not be the case if SEB is given during a different 
phase of the recall response. Accordingly, BALB/c mice were injected i.p. with IAV (PR8) 
and given a booster vaccination of IAV (SEQ.12) one month later. This time however, an 
injection of PBS or 50 μg of SEB was administered three days before the booster shot, or 
27 days after priming with IAV. As before, the percentage and number of IAV-specific 
TCD8+ were assessed by ICS for IFNγ one week after boosting. Unexpectedly, the 
percentage (Fig. 21A) and absolute number (Fig. 21B) were significantly decreased for 
every IAV-derived TCD8+ epitope save for the barely-detectable NP218-specific 
population.  
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Figure 21. SEB administration before a boosting dose of IAV (SEQ.12) decreases the 
TCD8+ response to IAV as measured 7 days later. The mice were primed with IAV 
(PR8) one month before boosting with IAV (SEQ.12). Three days before the boost the 
mice were injected with SEB or PBS. One week after boosting the (A) percentage and (B) 
absolute number of cells were measured by ICS for IFNγ. N=12 per group pooled from 3 
independent experiments. Bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***, 
p<0.001, unpaired Student’s t-test). 
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To dissect what was occurring with the TCD8+ when SEB was given before the boosting 
dose of IAV (and why there was such a striking reduction in the magnitude of the TCD8+ 
response to all IAV-derived epitopes), tetramer staining for NP147- and HA518-specific cells 
was carried out in conjunction with staining for detection of proliferation, death and 
anergy/exhaustion markers. Though neither epitope-specific TCD8+ population 
significantly upregulated PD-1 expression, the gMFI of Fas and LAG3, associated 
respectively with death and exhaustion, was significantly increased (Fig. 22) (39, 40). In 
addition, the intracellular expression of Ki67, which marks proliferation (41), was 
significantly reduced in TCD8+ specific for both epitopes. This demonstrates that SEB 
exerts different effects on TCD8+ specific for IAV dependant on the phase of the recall 
response. 
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Figure 22. Splenic TCD8+ specific for NP147 and HA518 display increased expression 
of anergy markers and lower Ki67 expression when SEB is given before the boosting 
dose of IAV. Seven days after the boosting dose of IAV splenocytes were stained with 
NP147 and HA518-specific tetramers in conjunction with a cocktail of fluorescent antibodies 
directed against indicated anergy, death and proliferation markers. The gMFI for each of 
these markers was determined for the tetramer+ populations for both the PBS and SEB-
injected animals. N=4 per group. Bars represent mean +SEM (*, p<0.05, **, p<0.01 and 
***, p<0.001, unpaired Student’s t-test). 
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3.10 Local TCD8+ responses to intranasal IAV infection are 
not negatively affected by SEB. 
SEB, when injected locally into the peritoneal cavity, can nevertheless exert a systemic 
effect (42). Therefore, an i.p. injection of SEB may influence TCD8+ responses in distant 
sites such as the lungs. Since IAV naturally manifests as an upper respiratory infection, it 
is possible that SEB introduced i.p. may affect IAV-specific TCD8+ responses in the lungs 
and airway. To model the effect of i.p. SEB on the pulmonary TCD8+ response to IAV, 
BALB/c mice were injected with PBS or 50 μg of SEB before infection with a sub-lethal 
dose of IAV delivered intranasally. The mice were then monitored for weight loss until the 
peak IAV-specific TCD8+ response on day 10 (43), after which they were sacrificed to 
obtain cells from the spleen, lungs and bronchoalveolar lavage (BAL) fluid. Without IAV 
infection, i.p. SEB alone did not induce any significant weight loss as compared to 
uninfected, PBS-injected control mice (Fig. 23). Both the PBS- and SEB-injected mice that 
were infected with IAV lost significantly more weight than uninfected mice, though 
injection with SEB had no effect on weight loss in the IAV-infected group. 
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Figure 23. Weight loss of BALB/c mice infected intranasally with a sublethal dose of 
IAV (PR8) or PBS three days after intraperitoneal injection of SEB or PBS. 
Uninfected and SEB-only mice were intranasally instilled with 25 μL of PBS alone to 
control for inoculum volume. Mice were euthanized if weight loss exceeded 20% of their 
starting weight. Each point represents mean of percent starting weight for mice in each 
group ±SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, Two-way ANOVA). 
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Injection of SEB had a modest effect on IAV-specific primary TCD8+ responses in the 
spleen, significantly increasing the number of NP147-specific TCD8
+ and decreasing the 
response to the two most subdominant epitopes (Fig. 24A). However, there was no 
significant difference in the numbers of IAV-specific TCD8+ in either the lungs (Fig. 24B) 
or BAL (Fig. 24C) of SEB- versus PBS-treated mice. While SEB was clearly able to exert 
systemic effects in this model (as shown by the changes to splenic TCD8+ numbers), local 
TCD8+ responses to IAV infection in the context of replicative IAV infection were 
unaffected. 
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Figure 24. Response to IAV infection in the spleen, lungs and BAL of BALB/c mice 
treated with PBS or SEB prior to virus exposure. Mice were infected with a sublethal 
dose of IAV 3 days after SEB or PBS injection. Ten days after IAV infection the spleen, 
lungs and BAL were collected from the mice for enumeration of IAV-specific TCD8+ using 
ICS for IFNγ expression. (A) Splenic data is representative of the absolute number of 
epitope-specific cells. Both the (B) lung and the (C) BAL data represent pooled samples 
from 5 experiments. The N value varies per group (see legends), pooled from 5 independent 
experiments. Bars represent mean +SEM (*, P<0.05, **, P<0.01 and ***, P<0.001, 
unpaired Student’s t-test). 
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Though there was no effect of SEB on the amount of IAV-specific TCD8+ in the lungs or 
BAL, it is possible that SEB-induced changes to TCD8+ function could be manifested in 
terms of changes in IAV titre within the lungs and airways. Accordingly, the effect of SEB 
injected i.p. on viral titre in the lungs was assessed on day 4 post-infection, when viral titres 
should be at their highest (44). Measurement of IAV titre is complicated due to IAV 
infection resulting in the production of a high number of non-infectious viral particles (45). 
Thus, viral titre was quantified using methods that detect infectious particles as well as 
methods that detect total particle release. To enumerate the former, diluted preparations of 
BAL and lung homogenate were used in a TCID50 assay, which quantifies relative amounts 
of infectious virus per unit of starting material (46). This assay relies on the ability of IAV 
to infect monolayers of MDCK cells, which also allow virus release after infection (47). 
The viral progeny can be detected by the ability of particles collected from culture 
supernatants originating from the infected monolayers to induce agglutination of chicken 
red blood cells (48). Though infectious virus was detectable in samples from both PBS- 
and SEB-treated animals, there was no significant difference in the amount of infectious 
virus (Fig. 25). 
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Figure 25. IAV titre in the lungs and BAL fluid of mice infected 4 days prior with IAV 
(PR8). Three days before infection the mice were given PBS or SEB i.p. Titre was assessed 
by the ability of increasing dilutions of BAL or lung homogenate to infect a monolayer of 
MDCK cells. The presence of virus after washing, incubation and infection was determined 
by the ability of the culture supernatant to induce agglutination of chicken red blood cells. 
N=10 per group, pooled from 3 independent experiments. Bars represent mean ±SEM (*, 
p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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The same samples from the lung and BAL were also subjected to RT-PCR to detect copies 
of the viral m1 gene, which is generally carried as one copy per virus (49). In addition, the 
M1 protein is more highly conserved than outer membrane proteins like HA or NA as even 
small changes to critical residues affects its function (50, 51). RT-PCR can detect both 
infectious and non-infectious particles, which could reveal if SEB treatment increased 
release of defective virus particles. The amount of starting material used in the reaction 
was normalized based on volume (BAL) or weight (lung tissue) before extraction of total 
RNA from the samples. Similar to the quantification of infectious virus, there was no 
significant difference in the amount of total virus detectable in the PBS- versus SEB-treated 
mice (Fig. 26). These results indicated that i.p. SEB administration had no effect on the 
ability of the BALB/c mouse immune system to control viral titre. 
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Figure 26. Relative number of IAV viral particles in the lung and BAL of mice 
infected with sublethal IAV (PR8) after i.p. injection of SEB. Mice were injected with 
PBS or SEB 3 days before intranasal infection with IAV. Four days after infection the mice 
were sacrificed to obtain lungs and BAL fluid. RT-PCR for the presence of the viral m1 
gene was carried out these samples, which were the same as those used to evaluate 
infectious viral titre in Figure 25. N=10 per group, from 3 independent experiments. Bars 
represent mean ±SEM (*, P<0.05, **, P<0.01 and ***, P<0.001, unpaired Student’s t-test). 
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To confirm that the SEB stock used for the intranasal IAV experiments could be used to 
recapitulate previously reported effects on TCD4+ responses (19), BALB/c mice were 
injected with PBS or SEB i.p. before i.n. infection with 0.3 MLD50 IAV. Three weeks later 
the mice were sacrificed and bled through cardiac puncture to obtain blood samples. The 
serum from each mouse was then isolated before being investigated for the amount of IAV-
specific IgM and IgG2b present using an ELISA. IAV-specific IgM is present in the blood 
before IAV infection and should be detectable regardless of experimental treatment (52). 
IAV-specific IgG2b is only detectable in the serum after IAV infection and is capable of 
neutralizing IAV (53). Plates were coated with IAV-infected MDCK cell lysate before 
serum samples were applied. Equal amounts of IAV-specific IgM were found in samples 
from both treatment groups (Fig. 27A), which was expected since mice have pre-formed 
IgM that can bind IAV (54). In contrast, at most dilutions the titre of IAV-specific IgG2b 
was significantly decreased in the SEB-injected mice as compared to those injected with 
PBS (Fig. 27B). This observation matches what had been previously reported for the effect 
of SEB on the ability of TCD4+ to provide help for Ab production (19). 
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Figure 27. Antibody titres in the serum of mice treated with SEB or PBS before IAV 
infection (0.3 MLD50). Three weeks after IAV infection, the mice were bled and the serum 
collected for use in an ELISA. The plates were coated with IAV-infected MDCK lysate 
before incubation with the diluted serum samples, after which the binding of (A) IgM or 
(B) IgG2b was determined. N=8 for each group. Bars represent mean ±SEM (*, p<0.05, 
**, p<0.01 and ***, p<0.001, 2-way ANOVA). 
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3.11 SEB greatly augments the immunodominant NP147 
response in the context of IAV-specific memory. 
While primary and recall TCD8+ responses are augmented by SEB administration (with 
the notable exception of scenarios in which SEB is given before boosting with SEQ.12), 
an important component of the immune response when considering anti-IAV immunity is 
the memory phase. IAV is a common pathogen, and in terms of human immunity most 
individuals will have a pre-existing pool of memory TCD8+ specific for IAV. However, 
since IAV is not a natural mouse pathogen, experimental models utilizing mice necessitate 
induction of memory through IAV exposure before a response can be detected. The mouse 
TCD8+ response to IAV is largely directed against the immunodominant NP147 epitope 
(55), and our initial experiments demonstrated that the memory response is almost entirely 
directed at this epitope. To determine the effect of i.p. SEB injection on this memory 
response to IAV, BALB/c mice were vaccinated with IAV i.p. and left to develop a CD8+ 
memory population for 2 months. At the end of this period the mice were injected with 
PBS or 50 μg SEB i.p., followed three days later by sacrifice and harvesting of splenocytes. 
Even two months after injection, SEB was able to significantly expand the number of 
NP147-specific splenic TCD8
+ (Fig. 28). 
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Figure 28. The NP147- specific memory CD8+ T cell population is expanded by 
contact with SEB. Mice were injected with IAV i.p. 2 months before injection of SEB. 
Three days after SEB/PBS injection, NP147-specific TCD8
+ responses were measured via 
ICS for IFNγ. N=16 per group, pooled from 4 independent experiments. Bars represent 
mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, Student’s t-test). 
 
 
 
 
 
 
 
 
 
 
 
128 
 
A separate cohort of IAV memory mice were used to assess the killing ability in vivo of 
these SEB-expanded NP147-specific TCD8
+. As before, BALB/c mice were injected with 
IAV i.p. two months before injection of PBS or SEB i.p. On the flow cytometer, the CFSE 
peak corresponding to the NP147-pulsed target cell population was noticeably smaller in the 
samples from the SEB-treated mice as compared to those from the PBS-treated animals 
(Fig. 29A). Calculation of the percent specific killing of NP147-pulsed  target cells showed 
a statistically significant increase for the SEB-injected animals as compared to those that 
had received PBS three days prior (Fig. 29B). These results demonstrate that SEB is 
capable of augmenting the magnitude as well as cytotoxic effector capability of memory 
IAV-specific TCD8+. 
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Figure 29. IAV memory mice injected with SEB three days prior to in vivo killing 
assay have significantly more killing of NP147-pulsed target cells. Mice were injected 
i.p. with IAV before resting for 2 months. The animals were then injected with PBS or SEB 
3 days before evaluation of NP147-specific cytotoxicity by in vivo killing assay. (A) 
Representative CFSE peaks from PBS- and SEB-injected IAV memory mice. The NP118 
(irr) peak represents splenocytes that had been pulsed with the immunodominant peptide 
from lymphocytic choriomeningitis virus (LCMV), which are not killed by TCD8+ in the 
experimental mice. (B) Quantification of percent specific killing based on loss of 
fluorescence from NP147-pulsed target cells. N=7 for PBS and N=6 for SEB, pooled from 
3 independent experiments. Bars represent mean ±SEM (*, p<0.05, **, p<0.01 and ***, 
p<0.001, unpaired Student’s t-test). 
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3.12 Human IAV-specific memory responses are augmented 
by SEB. 
Similar to the IAV-specific memory response in the BALB/c mouse model, the human 
memory TCD8+ response in HLA-A2+ individuals is largely directed against one epitope, 
abbreviated here as M158 (56). Since IAV is a natural human pathogen, almost every 
individual in the human population will have come into contact with IAV and thus have a 
population of memory TCD8+ specific for the virus. In addition, other studies have shown 
that the M158-specific cell population in HLA-A2
+ individuals (who comprise a large 
proportion of the Caucasian population (57)) largely uses the Vβ17 region in the TCR (58). 
This Vβ region binds SEB with high affinity (59), potentially making M158-specific 
memory TCD8+ highly susceptible to SEB-induced activation and proliferation. PBMCs 
were isolated from healthy HLA-A2+ individuals by density gradient centrifugation before 
culture with SEB and interrogation with M158 tetramer on days 0 (freshly isolated), 4, 7 
and 11. The sample plots shown in Figure 30A shows the typical course of the in vitro 
response to SEB, quantified in terms of percentage in Figure 30B and in terms of absolute 
number in Figure 30C. M158-specific TCD8
+ appear to be reduced in terms of absolute 
number when the population is detected by tetramer staining on day 4. However, this 
population is increased relative to PBS on day 7 and greatly expanded by day 11, 
suggesting that this loss of detection is due to internalization of the TCR rather than 
deletion or anergy. 
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Figure 30. Human M158-specific memory TCD8+ are expanded by SEB. Purified 
PBMCs were stimulated with either PBS or SEB on day 0 followed by staining for CD3 
and CD8 along with M158 tetramer. This staining was repeated on day 4, 7 and 11, with 
washes being carried out to remove residual cytokine and SEB on day 3 and 4. (A) Sample 
FACs plots from one donor. (B) Fold change of M158-specific memory TCD8
+ based on 
percentage of the total TCD8+ population and by (C) total number per million cells. N=8 
per group pooled from 8 independent donors. Bars represent mean +SEM (*, p<0.05, **, 
p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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To determine if other SAgs that bind human Vβ17 can result in the same expansion of 
M158-specific memory TCD8+, PBMCs from four HLA-A2
+ donors were isolated and 
used in an analogous experiment utilizing MAM instead of SEB. MAM binds to and 
activates human Vβ17+ cells, even though this SAg is derived from a mouse-adapted 
pathogen (60). Though the results did not reach statistical significance, there is a trend 
towards an expansion of the M158-specific population in the MAM-treated group versus 
the PBS-treated control similar to that observed in the experiments using SEB (Fig. 31). 
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Figure 31. M158-specific memory CD8+ T cells from healthy human donors expand 
in the presence of MAM SAg. PBMCs were harvested and cultured with MAM or vehicle 
control for 11 days. Staining for M158-specific cells was carried out as for Figure 29. Fold 
change is expressed relative to the percentage of freshly isolated M158 tetramer positive 
cells. N=4 per group pooled from 4 independent donors. Bars represent mean ±SEM (*, 
p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test). 
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While the memory TCD8+ cells that are specific for M158 in HLA-A2
+ individuals are 
known to predominantly use Vβ17 in their TCR, the immunodominant response to pp65495 
derived from CMV does not share this characteristic (61). In fact, the pp65495-specific 
TCD8+ in HLA-A2+ humans has been shown to use a large variety of different Vβ regions, 
many of which cannot bind SEB. CMV is another virus for which specific immunity can 
be found in most individuals, as most North Americans have been exposed to the virus in 
early childhood. If possession of an SEB-reactive Vβ region is what drives the SEB-
induced expansion of M158-specific TCD8
+, then the pp65495-specific TCD8
+ should show 
no such response. Three healthy donors that have both detectable populations were bled 
and PBMCs were isolated, stimulated with SEB and stained as in the other human PBMC 
experiments. The only change was the inclusion of staining on each day for pp65495-
specific cells as well as those that are M158-specific. As anticipated, the M158-specific 
population was expanded by contact with SEB (Fig. 32A) while the pp65495-specific 
population was not (Fig. 32B). These data strongly suggest that the expansion of the M158-
specific population was due to the expression of a Vβ17+ TCR. 
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Figure 32. SEB induces expansion of M158-specific TCD8+ but not memory TCD8+ 
specific for CMV-derived pp65495. PBMCs were harvested from healthy donors and 
cultured as in Figure 29. Surface and tetramer staining was carried out as in Figure 29 as 
well, save for the inclusion of the CMV pp65495-specific tetramer. Each point shows data 
from one sample harvested from in vitro culture. Data from each donor is stacked in vertical 
columns and is collected from the same experiment. (A) The effect of SEB versus PBS on 
the expansion by fold change of M158-specific TCD8 per day from three healthy human 
donors. (B) The effect of SEB versus PBS on the expansion by fold change of pp65495-
specific TCD8+ per day from the same three healthy human donors, run in parallel. 
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As is the case in the mouse system, expansion of human TCD8+ does not necessarily 
correlate with increased effector function. It is possible that the M158-specific cells are 
expanded by SEB but remain anergic to stimulation by cognate peptide. To address this, 
PBMCs from three healthy human donors were isolated and cultured with SEB as in 
Figure 30 for 11 days. The cells were then stained with the M158-specific tetramer 
conjugated to Alexa Fluor 647 before isolation of tetramer+ cells using magnetic labelling 
and separation. These purified M158-specific cells were then used as effectors in a 
chromium release assay. Briefly, effector cells were incubated with a target cell line that 
was pulsed with the peptide of interest (in this case M158) and labelled with radioactive 
chromium. The effector cells were then incubated with the target cells at different ratios 
for a set amount of time, and specific killing of the target cells was measured by the 
release of chromium into the supernatant. As a control for background killing the effector 
cells were also incubated with labelled target cells that had not been pulsed with peptide. 
For all three donors the data show that M158-specific TCD8
+ that have been treated with 
SEB are capable of specifically killing target cells pulsed with cognate peptide, and that 
the amount of killing positively correlates with increasing effector:target cell ratios (Fig. 
33). These data show that the M158-specific population that have been expanded by 
contact with SEB are functional, rather than being anergic or exhausted. 
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Figure 33. M158-specific TCD8+ from three healthy donors that have been incubated 
with SEB display the ability to kill target cells pulsed with M158 peptide. Target cells 
consisted of the HLA-A2+ cell line T2 pulsed with M158 peptide. After adding the target 
cells to the effectors killing was allowed to proceed for 8 hours, followed by collection of 
the culture supernatants that were evaluated for radioactive chromium content using a 
gamma radiation counter. Data for each donor (flow plots and percent specific killing) is 
shown stacked in vertical columns. Points correspond to mean ±SD of technical replicates, 
with N=4 for Donor 7 and N=3 for Donor 6 and Donor 1 (*, p<0.05, **, p<0.01 and ***, 
p<0.001, unpaired Student’s t-test). 
 
 
 
 
 
 
 
See Figure 29A 
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Chapter 4: Discussion 
In this work, we have shown that the effect of bacterial superantigens on epitope-specific 
TCD8+ responses is markedly different than what had been previously reported with 
respect to the effect of SAgs on bulk TCD8+ responses (1, 2, 3, 4). Though the ability to 
detect splenic TCD8+ bearing SEB-reactive Vβ regions through surface staining for TCR-
Vβ is indeed diminished (after a three-day stimulation in vitro), our data suggest that this 
is likely due to SAg-induced activation and the resultant TCR internalization rather than 
deletion or anergy of the responding cells. Using a mouse model of IAV vaccination in 
conjunction with administration of SAgs, we have shown that bacterial SAg can actually 
be used to boost primary epitope-specific TCD8+ responses to IAV, though the timing of 
SAg administration is crucial in the context of the recall response. In addition, the SAg-
boosted epitope-specific TCD8+ have enhanced effector function as measured by their 
ability to kill peptide-pulsed target cells in an in vivo killing assay. However, despite the 
ability of SAg to induce systemic effects on the immune system, SEB injected into the 
peritoneal cavity has no effect on local responses to i.n. IAV infection. Returning to our 
investigation in the vaccination model of IAV exposure, we found that bacterial SAg also 
enhanced memory response to IAV vaccination in terms of magnitude and effector 
function. Furthermore, extension of our work to studies involving human memory TCD8+ 
specific for IAV revealed that SAg also effectively increases the magnitude and effector 
function of pre-existing IAV-specific memory cells in HLA-A2+ individuals rather than 
inducing deletion or anergy. 
Previous studies focused on the effects of SAg on T-cell responses have often examined 
TCD4+ cells, with the effect of TCD8+ somewhat relegated to a secondary concern (4, 5). 
Most studies focusing on TCD8+ also relied on the use of surface markers or tetramers to 
detect the cells (2, 6), which can be problematic given the ability of certain bacterial SAg 
to induce TCR internalization (7, 8). Indeed, we observed a loss of detectability when using 
α-Vβ Abs or tetramers to detect the presence of TCD8+ at early time points after SEB 
administration or exposure. Our use of an ICS as the primary method for the detection of 
epitope-specific TCD8+ responses circumvents this problem by relying on the expression 
of intracellular IFNγ in lieu of TCR on the surface. In addition, our study is the first to 
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examine the effect of SAg on many different epitope-specific TCD8+ responses 
simultaneously, allowing us to examine the relative effects of SAg-induced changes on the 
ID hierarchy. Our choice of a BALB/c mouse model was also fortuitous as BALB/c mice 
possess increased sensitivity to SEB in comparison with other mouse strains (9), without 
the morbidity upon SAg injection into humanized mice (10). This enabled us to dissect 
changes to the TCD8+ ID hierarchy in detail without the confounding effects of weight loss 
or cytokine storm among other deleterious effects of SAgs. 
The initial result of enhanced responses to select TCD8+ epitopes in SEB-treated mice in 
the context of the primary response to IAV vaccination (Fig. 3) was unexpected. This was 
because the in vitro data generated by us (Fig. 2) and other groups showed contraction of 
SAg-stimulated cells after an initial period of proliferation. In addition, clinical evidence 
of immune suppression after human exposure to bacterial SAg (such as that after the 
resolution of sepsis) also led us to expect an immunosuppressive effect of SAg in our model 
(11, 12). This may still be true in certain contexts, but our results demonstrate that careful 
evaluation of experimental methods, timing and doses is necessary to isolate the effect of 
a given SAg on a defined set of TCD8+ responses. 
We showed that administration of SEB before vaccination with IAV increased the 
magnitude of the TCD8+ response to select IAV-derived epitopes (Fig. 3). This increase 
was noted in the local response to IAV in the peritoneal cavity, as well as the systemic 
response to IAV as measured in the spleen. This experimental setup was designed so that 
IAV was introduced into the mice at the peak of SEB-induced proliferation (13). Prior to 
SEB exposure, these mice are known to have a pool of naïve TCD8+ clones specific for 
IAV-derived epitopes (14). The naïve cells specific for NP147 and HA518 are able to bind 
and be activated directly by SEB, as these clones likely possess Vβ regions sensitive to 
SEB, as demonstrated by our Vβ profiling experiments during the primary response. It is 
possible that these clones are expanded by SEB, and that introduction of IAV into the 
system via vaccination acts to boost proliferation of these populations. This model would 
explain why administration of SEB before immune contact with IAV leads to expansion of 
epitope-specific populations bearing SEB-reactive Vβ regions while other populations 
(such as TCD8+ specific for PB2289) are not significantly expanded over the analogous 
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population in PBS-injected control mice. Another possibility is that SEB remains in the 
peritoneal cavity and blood until after administration of IAV, augmenting the proliferation 
of select IAV-specific clones. This scenario is highly unlikely, as SEB rapidly binds 
receptors in vivo (15, 16). 
Despite the inherent problems with detection of epitope-specific TCD8+ with tetramers 
after contact with SAg, we wanted to ensure that the IFNγ+ cells detectable by ICS 
represented the whole population of epitope-specific TCD8+, not just those that are capable 
of expressing IFNγ. We reasoned that SAg-induced down-regulation of the TCR would not 
be an issue at the time point examined, 10 days after initial contact with SAg. Our tetramer 
staining experiments agreed well numerically with the data obtained from ICS, suggesting 
that the population identified in the ICS experiments represents the total respective epitope-
specific populations (Fig. 7). It may also be worthwhile to confirm this by performing an 
intracellular stain with tetramer, though my previous experiments with MHC I tetramer 
have shown this to be a difficult and time-consuming experiment to optimize.  
The question of why some epitope-specific TCD8+ populations display preferential use of 
certain Vβ regions remain unanswered by our study, though Vβ region analysis of the 
NP147- and HA518-specific responses suggest that possession of SAg-reactive Vβ regions 
enables their selective expansion (Fig 13). Data from human studies of the M158-specific 
TCD8+ response in HLA-A2+ individuals, which largely use the Vβ17 region in their TCR, 
shows that this Vβ selection is driven by binding efficiency to cognate peptide:MHC I 
complexes (17). Selection of the Vβ17 region results in a TCR with a relatively flat surface 
around the peptide-binding groove, which facilitates interaction with a comparatively large 
variety of peptide:MHC complexes (18). A similar phenomenon could be driving restricted 
Vβ region selection for the NP147- and HA518-specific TCD8+ responses in the BALB/c 
mouse model. 
Our experiments with the SAgs MAM and SEA reinforce the conclusion that selective 
expansion of the NP147- and HA518-specific responses are driven by SAg-reactive Vβ 
expression. We were fortunate to find a mouse-adapted SAg that could bind Vβ8, namely 
MAM (19, 20). A repeat of the same primary experiment that had been performed with 
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SEB revealed similar expansion of the Vβ8-bearing NP147- and HA518-specific populations 
(Fig. 14). It is interesting to note how similar the effect on the IAV-specific response was, 
given that SEB is derived from Staphyloccoccus and MAM is produced by a completely 
unrelated Mycoplasma. This suggests that the main determinants of the SAg-mediated 
effect are the characteristics of the T cell population that is capable of being bound by the 
SAg. Accordingly, even though SEA is derived from the same bacterial species as SEB, 
there was no effect on the NP147- or HA518-specific TCD8
+ responses (Fig. 15), as SEA is 
incapable of binding Vβ8 (21).  
Reversing the order of IAV and SEB administration shows that the enhancement of IAV-
specific TCD8+ responses is not confined to one particular experimental schedule. Rather, 
vaccination with IAV before exposure to SEB either 4 (Fig. 16) or 7 (Fig. 17) days later 
produced significantly enhanced responses in terms of the magnitude for most epitope-
specific TCD8+ populations, even those (such as cells specific for PB2289) that do not 
predominantly express SAg-reactive Vβ regions.  In this case SEB is boosting immune 
responses to IAV that are already underway, so that the cells are in a state of proliferation 
rather than resting. The effect of SEB on the kinetics of the primary TCD8+ response to 
IAV as elucidated during our time-course experiments may also shed some light on why 
these later experiments, those reversing the order of IAV and SAg administration, show 
increases in the epitope-specific populations that are not tied to Vβ expression. At later 
time points, such as day 9 and 11 after IAV injection, we observed that the PB2289-specific 
population has started to expand significantly in the SEB-treated mice compared to the 
PBS controls. This later expansion could be the result of proliferation induced by the 
production of cytokines by SEB-responsive populations (22, 23). This same cytokine 
production could be driving the significant increases in most populations of IAV-specific 
TCD8+ observed in the IAV-before-SEB experiments. A good follow-up experiment to test 
if this is indeed the case would be to delete all SEB-reactive TCD8+ from the mouse system 
and inject the animals with SEB to see if any IAV-specific populations are expanded. 
Alternatively, NP147-specific TCD8
+ could be isolated from SEB-injected mice and 
cultured with PB2289-specific cells to see if the latter population expands. This setup is 
technically easier and potentially less problematic than deleting SEB-reactive cells in vivo, 
though it is a more artificial system.  
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Our functional readouts of TCD8+ ability show that SEB increased the effector capability 
of TCD8+ as well as the magnitude of this response. CD107a detection assays showed that 
after simulation with peptide, more TCD8+ positive for IFNγ and CD107a were detectable 
in the SEB-treated mice as compared to PBS-treated mice (Fig. 9). This suggests that SEB 
does not impair the ability of TCD8+ to degranulate in response to IAV and actually 
increases the abundance of the population that is able to do so. Interestingly, there was a 
trend towards decreased amount of CD107a expression per cell on TCD8+ from SEB-
injected mice, although the difference was small and not statistically significant for most 
peptides. If this trend is biologically meaningful it is possible that contact with peptide 
subsequent to activation by SEB leads to activation-induced cell death at least in some 
cases, causing a selective loss of the highest CD107a expressers (24). However, if this is 
taking place the number of cells thus affected must be small, as the total number of epitope-
specific CD107a+ cells is still increased in the SEB-injected mice.  
The in vivo killing assays in SEB- versus PBS-injected mice showed that SEB significantly 
enhanced IAV-specific killing in a more biologically relevant readout of TCD8+ effector 
function than in vitro degranulation assays (Fig. 10). This enhancement was detectable in 
both the SEB-before-IAV and the IAV-before-SEB primary response models. As part of 
the in vivo killing assay, virus-specific cells in the spleen of the SEB injected mice must 
recognize their cognate peptide in the context of MHC I and kill their target, as would occur 
in the case of natural infection with IAV. Unfortunately, this assay cannot distinguish 
whether or not SEB increases the killing ability of TCD8+ on a per cell basis (i.e. whether 
SEB enhances “serial killing” by TCD8+ (25, 26)) and/or whether the increased killing is a 
product of increased numbers of virus-specific cells in the spleen.  
Our next set of experiments was aimed at examining how the strain of IAV used for 
vaccination may influence how TCD8+ react to SEB. Different strains of IAV are known 
to induce different CD8+ T cell responses in terms of magnitude and peptide recognition 
(27). Examples from cases of human infection include the relatively modest immune 
responses to the 2009 pandemic H1N1 compared to the massive immune activation seen 
during the 1918 Spanish flu pandemic (28, 29). We used four different strains of IAV, two 
artificially modified in the lab (J1, X31) and two derived from naturally circulating strains 
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(NT60, HK) to address this. All four strains have a core derived from PR8, so any epitopes 
derived from the interior proteins of the virus (NP, PB2) will be identical to those derived 
from PR8 (30, 31). This enabled me to detect TCD8+ specific for these epitopes via ICS 
using PR8-derived epitopes that we have available. We found that the effect of SEB on 
virus-specific TCD8+ was the same for cells elicited in response to vaccination using all 
four viruses as compared to the response to PR8 vaccination (Fig. 11). The relatively more 
modest magnitude of the TCD8+ responses elicited by vaccination with the naturally-
derived NT60 and HK strains can likely be explained by the fact that these viruses are not 
mouse-adapted and thus less immunogenic in mice (32). It would also be interesting to 
perform this experiment with an IAV strain that encodes a highly cytotoxic version of the 
PB1-F2 protein. PB1-F2 induces cell death (33), and the expression of a particularly 
virulent version may tip the balance in SEB-activated cells from activation to anergy. 
Our next step was to see if SEB had the same effect on TCD8+ specific for IAV when IAV-
derived peptides were presented in the context of an unrelated virus. We used two strains 
of rVV that encode NP147 and HA518, respectively, as ES minigenes (34). This allowed me 
to examine the effect of SEB on TCD8+ specific for the vaccinia and IAV epitopes 
simultaneously. In addition, expression of NP147 and HA518 as ES minigenes bypasses TAP 
pathway by fusion of the immunogenic peptide to an endoplasmic reticulum targeting 
sequence (35). This increases the antigenicity of the expressed peptides so that robust 
TCD8+ responses can potentially be measured (36). This experiment also allowed me to 
examine the effect antigen presentation pathway may have on how SEB-stimulated TCD8+ 
respond to their cognate peptide, as rVV minigenes are usually presented through direct 
priming while IAV-specific responses arise through a mix of cross-priming and direct 
priming (37, 38, 39). Interestingly, we found that the TCD8+ response to rVV as well as 
the encoded IAV-derived epitopes was significantly decreased in the SEB-injected 
animals. Another important difference between IAV and rVV that could have influenced 
our results is that while i.p. injection of IAV does not result in viral replication (40), i.p. 
injection of rVV does (41). This could affect antigen availability as well as causing a loss 
of certain cell types due to virus-induced cell death in the case of rVV injection (42). To 
address these possibilities, follow-up experiments should include a time course for the 
effect of SEB on the kinetics of the virus-specific TCD8+ response, similar to what we have 
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done for IAV vaccination. In addition, a repeat of this primary experiment should be carried 
out in female mice to allow enumeration of viral titres in the ovaries (43) in order to gain 
a clearer picture of whether the presence of SEB could have an indirect effect on viral 
replication.  
Our investigation into the effect of SEB on the TCD8+ response to active viral infection 
also yielded somewhat unexpected results. Previous studies have shown that administration 
of SEB intranasally can be highly lethal (44), and that injection of SEB at certain times 
during the response to IAV infection can result in significant mortality as well (45). 
Combined with evidence showing that injection of SEB i.p. can induce lung pathology 
(46), I decided on an i.p. route of SEB administration for use in our mouse model of IAV 
infection. I also chose to use a sub-lethal dose of IAV in order to be able to harvest lung 
tissue and BAL from mice at the peak of the TCD8+ response to i.n. IAV, which is after 
peak mortality (47). Monitoring of the infected mice revealed no difference in weight loss 
induced by SEB administration, with or without IAV infection (Fig. 23). Analysis of the 
TCD8+ response by IAV-derived epitope via ICS also showed no changes in the lungs or 
cells retrieved from the airways via bronchoalveolar lavage (Fig. 24). Interestingly, the 
systemic effect of SEB on IAV-specific TCD8+ was still detectable in the spleen. At the 
sites of viral replication in the lungs and airway, it could be that the induction of other cells 
that play a role in the response to IAV (such as macrophages and NK cells (48, 49)) may 
be producing enough inflammatory mediators that drown out the effect of SEB. It may be 
possible to magnify any SEB-induced changes to lung TCD8+ by directly instilling SEB 
into the airway, but this is likely to produce mortality before the peak TCD8+ responses to 
IAV are reached. We also examined the effect of SEB on lung viral titres at their peak on 
day 4 after infection, but no significant differences were detected (Fig. 25 and 26). A 
follow-up experiment would be to see if clearance of the virus from the lungs is enhanced 
or delayed in the SEB-injected animals.  
The effect of SEB on the recall response to IAV in the context of a prime-boost vaccination 
regimen was particularly interesting for its revelation of the importance of timing with 
regards to the effect of SEB on TCD8+ responses. Elevated numbers of KLRG1- CD127+ 
memory precursors among epitope-specific TCD8+ after the primary response in SEB-
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injected animals (Fig. 19) suggested that recall responses to IAV may be augmented by 
SEB administration before the priming injection. Accordingly, mice were injected with 
SEB three days before priming with IAV i.p. One month later the mice were boosted with 
an i.p. dose of IAV (SEQ.12) before assessment of the secondary IAV-specific response 
after one week. As expected, the response to the IAV-derived epitopes that had been 
expanded during the primary response was elevated in the SEB-treated mice (Fig. 20). 
However, injection of SEB three days before the boosting dose of IAV resulted in a 
diminished TCD8+ response to all IAV-derived epitopes (Fig. 21). These cells expressed 
decreased levels of Ki67 and increased expression of Fas and LAG3 relative to cells from 
PBS-injected mice (Fig. 22). In this case, SEB may indeed be inducing deletion or anergy 
of virus-specific TCD8+. This could be due to the timing of the SEB and IAV doses; at day 
27 the IAV-specific TCD8+ are still in the contraction phase of the primary response to 
IAV. They then receive a strong proliferative signal from SEB binding, quickly followed 
by stimulation with their cognate antigen. This series of stimuli could result in activation-
induced cell death, accounting for the decreased numbers and Ki67 expression along with 
the increased expression of anergy and exhaustion markers. Future experiments should 
focus on the comparison of TCD8+ populations just prior to boosting or priming, since 
these results suggest that naive T cells react differently to SEB than those remaining after 
the primary response. 
Given the different results obtained from experiments with SEB administration during the 
recall response, we asked how memory cells specific for IAV react to SEB stimulation. We 
induced IAV-specific memory in mice by injecting the animals with IAV two months 
before injection with SEB. Three days after SAg administration we examined the 
percentage and numbers of epitope-specific TCD8+ by ICS. In the spleens of the SEB-
treated animals we found that that the percentage and number of cells specific for every 
IAV-derived epitope was significantly increased in the SEB-injected mice, though we 
focussed our attention on the NP147-specific response as it is the most immunodominant 
peptide and showed the greatest augmentation (Fig. 28). In addition, an in vivo killing assay 
examining the effect of SEB on the cytotoxic ability of these NP147-specific cells showed 
dramatically increased killing of NP147-pulsed splenocytes in the SEB-injected animals 
(Fig. 29). These results encouraged the investigation of the effect of SEB on IAV-specific 
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memory TCD8+ in humans, as the likelihood of an individual having developed anti-IAV 
immunity at some point in their life is very high (50). 
Studies have shown that most individuals with an HLA-A2+ haplotype will direct most of 
their IAV-specific TCD8+ immune response against the M158 peptide (51). The relative 
abundance of the HLA-A2 haplotype among individuals of Caucasian descent also make 
the TCD8+ response against this epitope an attractive choice for human IAV studies (52). 
We obtained blood from healthy HLA-A2+ donors, isolated PBMCs by Ficoll density 
gradient centrifugation and cultured these cells for 11 days in the presence or absence of 
SEB. On days 0, 4, 7 and 11 we stained the samples from each condition with M158-specific 
tetramer to enumerate IAV-specific memory TCD8+ (Fig. 30). For donors with a detectable 
population on day 0, we found that this population “disappeared” in terms of tetramer 
staining on day 4. We continued to follow this population in culture on day 7 and finally 
on day 11. On both days we detected expansion of these IAV-specific memory TCD8+, 
which suggests that our failure to detect them on day 4 was the result of TCR internalization 
rather than deletion. In addition, we found that this expansion was likely due to the 
predominant expression of Vβ17 in the M158-specific TCR (53), a Vβ region that is bound 
by SEB in humans (54). We tested this by repeating the culture experiment with the MAM 
SAg, which also binds human Vβ17 (55), and noticed the same expansion trend as for SEB 
(Fig. 31). This shows that the ability to enhance the magnitude of human memory TCD8+ 
to IAV is not confined to a SAg from a single microbial species. To further examine the 
role of Vβ in augmentation of human memory antiviral responses by SAg, we chose to test 
the effect of SEB on a memory population that did not predominantly express an SEB-
reactive Vβ region. Human memory TCD8+ specific for pp65495, the immunodominant 
epitope derived from CMV in HLA-A2+ individuals, is made up of a collection of cells that 
vary in their Vβ expression (56, 57). Comparison of the effect of SEB on M158-specific 
versus pp65495-specific cells from the same donors showed that SEB induced expansion of 
the former population while the latter remained relatively unchanged (Fig. 32). This further 
suggests that the Vβ composition of IAV-specific TCD8+ in HLA-A2+ individuals renders 
these populations especially susceptible to SAg-induced skewing.  
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Finally, we tested the effect of SEB on the ability of human M158-specific TCD8
+ to kill 
targets pulsed with cognate peptide. Since injecting SEB into humans and performing in 
vivo killing assays in humans are obviously out of the question, we isolated PBMCs from 
HLA-A2+ donors and cultured them in the presence of SEB for 11 days. On the final day, 
we harvested the cells and isolated M158-specific TCD8 for use as effector cells in a 
chromium release assay. For each of the three donors we recruited, the SEB-treated cells 
displayed effective specific killing of their peptide-pulsed targets after 8 hours of 
incubation (Fig. 33). This level of killing was significantly increased over unpulsed 
controls, showing that SEB was not inducing the TCD8+ to indiscriminately kill any target 
cell.  
Taken together, the results from the mice and human experiments revealed a possible role 
for bacterial SAg as a possible adjuvant for future IAV vaccines once their deleterious 
effects can be minimized. They can be used to boost responses to IAV-derived epitopes 
while conserving the ability of these cells to kill their cognate targets. Though the current 
vaccines against IAV rely on induction of strong Ab responses, this defence strategy only 
works for IAV strains for which we can formulate a preventative vaccine. Optimal defence 
against primary IAV infection with novel strains relies on effective TCD8+ responses (58, 
59), which can be boosted through therapeutic vaccination. Given the recent emergence of 
several novel highly pathogenic strains of IAV and the increasingly rapid spread of 
pandemic IAV strains around the globe (60), formulation of new therapies to boost TCD8+ 
responses against IAV is becoming imperative. My research also helps us to better 
understand the interactions between bacterial SAgs and IAV infection in terms of the 
impact on the antiviral TCD8+ response. Since the co-occurrence of infection by SAg-
producing bacterial strains and IAV remains a significant clinical problem (61, 62), 
understanding the effect of this interaction on the immune system could lead to better 
treatments for cases of bacterial-viral coinfection. 
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